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ABSTRACT: 
Cancer is a devastating disease, affecting millions of individuals every year. 
Though no cure exists for cancer at present, countless years of research have given rise to 
promising treatments such as Trastuzumab, Taxol, Tamoxifen, VP-16 and cisplatin. The 
majority of these treatments are non-selective thus affecting both normal and cancerous 
cells. Pancratistatin, a natural compound obtained from the Hawaiian spider lily, is 
known to be specific and selective in inducing apoptosis in multiple cancer cell lines 
through selectively targeting the mitochondria. In this study it was discovered that PST 
induced increased levels of cytosolic pro-apoptotic protein Bad in the cytoplasm as well 
as localization of Bax to the mitochondrial membrane. Release of Cytochrome c due to 
membrane permeabilization indicating the activation of the mitochondrial (intrinsic) 
pathway of apoptosis was initiated. 
Tamoxifen is a known anti-estrogen compound, which has the capability to 
induce apoptosis in estrogen receptor dependent breast cancers selectively. This 
compound is relatively non-toxic to normal cells. Recently, it was reported that 
Tamoxifen has the capability of destabilizing mitochondrial membrane potential. In 
combination with the anti-estrogen Tamoxifen, PST had a synergic effect in both 
estrogen receptor positive as well as estrogen receptor negative cells at lower doses than 
previously reported. Furthermore, whole cell reactive oxygen species levels were 
increased and mitochondrial destabilization was observed. Thus the present work 
provides evidence to support the observation that Tamoxifen might work through 
mechanisms distinct from the canonical estrogen receptor antagonism and act 
synergistically with PST. 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer 
Our bodies are immensely complicated machines made up of trillions of cells, 
each cell containing billions of base pair DNA. This DNA codes for proteins which carry 
out the roles necessary to maintain normal function and homeostasis within the cell. 
Protein function is dictated by the structure, which is in turn governed by the genetic code 
that serves as a blueprint for life. It is therefore mutations in a small group of critical 
genes (oncogenes) that results in uninhibited cell growth which ultimately leads to tumor 
development (Kliensmith 2006). The effects of the tumor as felt by the individual can be 
categorized as invasive; in which the cancer affects surrounding tissue or metastastatic; in 
that the tumor moves to other regions of the body (Kliensmith 2006). These factors lead 
to interference of normal bodily functions and if left untreated may lead to death. 
1.1.1 Cancer Statistics 
Cancer is a disease which has continuously plagued societies for thousands of 
years and even today it remains as one of the most frequently diagnosed and deadly 
diseases despite exhaustive efforts in cancer research. In 2008 it was projected by the 
Canadian Cancer Society that new cancer cases will reach 166,000 and cancer related 
mortality will approach 73,000 in Canada alone (www.cancer.ca). The most common 
types of cancers differ in males and females. In particular in males the most frequently 
diagnosed form of cancers include: prostate (20,400 new cases), lung (11,900 new cases) 
and colorectal (10,600 new cases). In Females the most highly diagnosed forms include: 
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breast (19,300 new cases), lung (9,300 new cases) and colorectal (9,100 new cases) 
(www.cancer.ca). 
1.1.2 Causes of Cancer 
Cancer is caused by a variety of factors including: diet, lifestyle, family health 
history and exposure to industrial chemicals (Ames et. al. 1995). It is therefore adequate 
to point out that cancer is not a disease with one cause; instead cancer is a heterogeneous 
disease, which arises from a life-time accumulation of mutations in very specific regions 
of DNA. This factor influences cancer cell development by causing mutations in the 
DNA of genes critical to cell growth, cell cycle maintenance and apoptosis inducing 
genes (tumor suppressor genes). Mutated versions of such genes are termed oncogenes. 
Proto-oncogenes are normal genes responsible for inhibition of apoptosis and 
propagation of cellular growth. When proto-oncogenes become mutated and become 
oncogenes they resume normal function, however, they do not respond to inhibitory 
stimuli leading to increased cell division, and inhibition to cell suicide stimulating factors 
(Osborne et. al. 2004, Weinberg 1996). Tumor suppressor genes in normal cells induce 
apoptosis when the conditions for growth are not met. These genes when mutated to 
oncogenes lack the normal function and thus prevent the initiation of apoptosis in cancer 
cells which contributes to cancer cell formation (Chabner, Roberts 2005, Weinberg 
1996). 
It has been found that lifestyle, environment and diet are immensely tied into 
cancer cell development and is responsible for approximately 80% of all cancers cases 
(Ames et. al. 1995). Compounds which reduce the body's capacity to dealing with 
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oxidative stress increase the propensity of oxidative damage to cellular DNA. The most 
common cause of such DNA mutation in cancer is smoking cigarettes. Tobacco products 
consumed by individuals are responsible for one third of all cancer cases. The exact 
mechanism of cancer cell development by these products is unknown, however it is 
postulated that these compounds reduce the amount of natural anti-oxidents circulating 
the body, thereby sensitizing individuals to oxidative stress induced DNA mutation 
(Ameset. al. 1995). 
1.2 Breast Cancer 
Breast cancer is the most highly diagnosed carcinoma in women, new cases of 
this disease are projected to reach 19,300 in 2008 (www.cancer.ca). For this reason it has 
been one of the most fiercely researched forms of cancer. Due to such research efforts 
great progress has been made in the understanding of this disease and its progression. 
1.2.1 Breast Cancer Development 
Breast cancer like all cancers is a genetically and clinically heterogeneous disease. 
The specific causes of this disease have been significantly studied and it has been shown 
to arise primarily as a result from the malignant transformation of mammary stem and/or 
progenitor cells (LaMarca, Rosen 2008). Post natal mammary gland development is 
coordinated by both systemic hormones and growth factors. In particular hormones such 
as progesterone and estrogen drive the development of mammary tissue through the 
actions of their respective receptors: progesterone receptor (PR) and estrogen receptor 
(ER) respectively (LaMarca, Rosen 2008). However, up-regulation of the proto-oncogene 
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estrogen receptor has been shown to increase the probability of breast tumor development 
(Mense et. al. 2008). Furthermore specific genes have been found to have a high 
frequency of mutation in breast cancer increasing the probability of disease development. 
In particular, it has been found that mutations in tumor suppressor genes: p53 and 
BRCA1 increases the propensity of breast cancer development (Gayther et. al. 1995). 
Estrogen receptors (ER's) are members of the nuclear receptor superfamily 
(NR's) and induce the pleiotropic effects of estrogen (Shao, Brown 2003). The effect of 
the estrogen receptor plays a critical role in the physiology and developmental processes 
of normal breast tissue by inducing expression of specific genes. At present two types of 
estrogen receptors have been discovered ERa and ER(3 which have distinctly opposite 
roles. Estrogen receptor a (ERa) plays a pivotal role in mammery cell development by 
acting as a transcription factor of key genes responsible for growth such as transforming 
growth factor receptor (TGF) and epidermal growth factor receptor (EGFR) (Mandlekar, 
Kong 2001). Interestingly it was found that ERa is antagonistic to the functions of ER0 
which primarily acts to suppress growth of the cell (Mandlekar, Kong 2001). Therefore 
the growth of ERa positive breast cancers has been shown to be accelerated in presence 
of estrogen (Mense et. al. 2008). 
Mutation in genes responsible for programmed cell death has been linked to 
breast cancer development. In particular, the tumor suppressor gene p53 has been shown 
to be mutated in approximately 30-50% of all breast cancer cases (Haider et. al. 1994). 
Normal p53 when activated is responsible for inhibition of cell cycle propagation and 
initiation of cell suicide via apoptosis. However, in breast cancer cells this mechanism is 
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inhibited by the lack of functioning p53 (mutated p53) and therefore genetic mutations 
propagate into daughter cells potentially leading to tumorigenesis (Haider et. al. 1994). 
Also, mutations in the tumor suppressor gene termed breast cancer susceptibility 
gene 1 (BRCA1) have been shown to increase the incidents of developing breast cancer 
(Gayther et. al. 1997). BRCA1 is a DNA damage response protein involved in DNA 
repair caused by ionizing radiation (Hongtae, Junjie 2008). Mutations in this gene 
therefore reduce the cells potential in DNA repair increasing incidence of further 
mutations and tumor development. In particular, germ line mutations in BRGA1 gene 
have been shown to occur in 80-90% of familial cases of breast cancer (Gayther et. al. 
1995). 
1.3 Apoptosis 
The cell consists of complex biochemical machinery that is critical to the normal 
homeostasis and survival of the organism as a whole. When a cell no longer suits the 
need of the organism it undergoes a suicide program termed apoptosis. Apoptosis was 
first discovered in 1972 by kerr et. al. who found that cell death processes can be 
categorized into two distinct forms: necrosis and apoptosis. 
1.3.1 Necrosis and Apoptosis 
Necrosis can be defined as pathological, inappropriate and passive. It is brought 
about by physical or chemical factors such as heat, pressure, injury and chemical damage 
(Szabo et. al. 2005). The changes within the cell upon such stimuli are random and do not 
exhibit any distinct pattern because they are not controlled by any internal biochemical 
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mechanism. Instead they bring about random damage to the many different organelles 
that are integrated within the cellular environment. Such damage causes inflammatory 
responses within the organism through the facilitated action of immune cells like 
macrophages (Haslett 1992). 
Apoptosis by contrast to necrosis can be defined as a physiological, appropriate 
and active process which simply acts to activate a complex biochemical pathway that acts 
to initiate cell suicide and remove the damaged cell from the organism. Initiation of this 
process can be activated by factors such as cellular receptors, DNA damage, growth 
factor deprivation and cell cycle arrest (Hickey et. al. 2001). 
Once initiated this process requires the input of energy in the form of ATP and the 
activation of proteases named caspases to orderly deconstruct the cell into very distinct 
and visible components. In general the process involves the ordered destruction of cells 
and phosphatidyl serine flipping which acts to recruit phagocytes which exhibit non-
inflammatory responses (Pandey et. al. 2000, Green, Reed 1998). Due to this order, 
distinct apoptotic features can be visualized under a light and fluorescent microscope 
including: DNA fragmentation, phosphatidyl serine flipping, membrane blebbing and 
mitochondrial membrane potential collapse (Duke et. al. 1996). 
Two distinct pathways exist in which a particular stimulus can induce apoptosis. 
The two pathways are termed intrinsic and extrinsic, however the ultimate effect of both 
pathways is the depolarization of mitochondrial membrane potential leading to 
permeabilization and the release of apoptogenic factors such as AIF, cytochrome C, and 
SMAC Diablo. 
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1.3.2 Extrinsic Pathway 
Apoptosis can be initiated by a specific group of death receptors on the surface of 
the cellular membrane termed TNF receptor (tumor necrosis factor). The TNF receptor 
family includes Fas receptor, TNF and TRAIL (TNF related apoptosis inducing ligand) 
(Degterev et. al. 2003). Apoptosis by the extrinsic method is initiated by ligands that bind 
to the receptor and induce a conformational change on the receptor which induces 
apoptotic events. One key event induced by ligand binding to "death receptors" is the 
recruitment of key proteins which form a death induced signaling complex (DISC) 
(Ashkenzai, Dixit 1998). Once formed, the DISC complex acts to activate caspase-8 
through cleavage of the zymogen procaspase-8 (figure 1-1). Caspase-8 then processes 
Bid to truncated Bid (tBid) which in turn acts to destabilize the mitochondrial membrane 
which releases apoptogenic factors that cause activation of caspase-3 (Ashkenzai, Dixit 
1998). Therefore, Bid activation into tBid links the extrinsic pathway of apoptosis to that 
of the intrinsic pathway (Chou et. al. 1999, McDonnell et. al. 1999, Korsmeyer et. al. 
2000). 
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Figure 1-1: The Extrinsic Pathway of Apoptosis 
,'Ligand 
Figure 1-1: The extrinsic pathway of apoptosis 
In the extrinsic pathway of apoptosis, the death receptors are activated by ligand binding, which leads to the 
formation of DISC (death inducing signaling complex) and the activation of caspase-8. Active caspase-8 
causes the activation of caspase-3 and the formation of tBid, both of which lead to apoptosis. 
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1.3.3 Intrinsic Pathway 
Intrinsic pathway begins with cellular stress induced internally such as DNA 
damage induced by DNA damaging agents such as: radiation, chemotherapies and 
reactive oxygen species (Kroemer, Reed 2000). The intrinsic process of apoptosis is 
centered on destabilization of mitochondrial membrane potential by pro-apoptotic 
proteins. 
When a DNA damaging agent is presented to a cell, the general intrinsic pathway 
which is followed includes activation of p53 transcription factor, which up-regulates pro-
apoptotic proteins including Bax. Bax, when activated, will localize to the outer 
mitochondrial membrane and induce mitochondrial destabilization. Bax can induce 
destabilization directly or indirectly. Direct mitochondrial pore formation through Bax is 
thought to occur by Bax homodimerization (figure l-3a). Indirect Bax induced 
mitochondrial pore formation is believed to occur mainly through the interaction with the 
PTP (protein transition pore) complex on the outer mitochondrial membrane (figure 1-
3b). Bax binding to the PTP induces opening of the PTP (Reed 2000). Depolarization of 
mitochondrial membrane potential leads to the release of apoptogenic factors such as 
cytochrome c, SMAC Diablo and AIF (Green and Reed 1998). 
Cytochrome c, once released from the mitochondria, forms an ATP dependent 
complex with APAF-1 (apoptosis activating factor-1) and caspase-9 termed the 
apoptosome (Ashkenazi, Dixit 1998). The apoptosome then serves the role of inducing 
activation of caspase-3 through cleavage of a zymogen procaspase-3 (figure 1-2). 
Caspase-3 is an enzyme which is a part of a broad family of enzymes termed aspartyl 
specifc cystienyl protease, which act via proteolysis through the cleavage of specific 
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recognition amino acid sequence (DEVD). Caspase-3 translocates to the nucleus when 
activated and targets key proteins for proteolysis such as ICAD (inhibitor of caspase-
activated DNase), once activated ICAD acts to cleave DNA in an ATP dependent manner 
and causes chromatin condensation (Li et. al. 1997). 
Smac/DIABLO (direct IAP binding protein with low pi) was found to be released 
from the mitochondrial membrane along with cytochrom C (Verhagen et. al. 2000). This 
protein was found to promote apoptosis by binding to and inhibiting IAP (inhibitor of 
apoptosis protein). IAP acts to inhibit caspases necessary to propagate the apoptotic 
signal cascade (Verhagen et. al. 2000). 
It was observed that a key apoptogenic factor exists which can bypass the caspase 
cascade all together and directly induce the effects of caspases. Apoptosis inducing factor 
(AIF) was found to translocate to the nucleus once released from the mitochondrial 
membrane and induce chromatin condensation and DNA degradation (Susin et. al. 
1999). 
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Figure 1-2: The intrinsic pathway of apoptosis, outer mitochondrial membrane permeablization by pro-
apoptotic proteins (tBid, Bax, Bok) leads to the release of cytochrome c forming the apoptosome and 
activating caspase-9, leading to caspase-3 activation. Simultaneously, AIF are released and trans-locates to 
the nucleus, where it induces DNA fragmentation. As well, Smac/Diablo is released which inhibits 
inhibitors of apoptosis proteins leading to prolonged caspase activation. 
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1.4 Pro/Anti-apoptotic Proteins 
Bcl-2 is a family of pro and anti-apoptotic proteins which contain homologous 
domains; these domains are termed Bcl-2 homologous domains (BH domains) which 
range from BH1-BH4 (Hunter et. al. 1996, Chinnadurai, Lutz 1995). Interaction of 
pro/anti-apoptotic proteins involved in apoptotic regulation mainly involves the BH 
domain. Currently, there are approximately 15 known pro/anti-apoptotic proteins. Bcl-2 -
family members share one or more Bcl-2 homologous (BH) domain and are divided into 
two main groups according to whether they promote (pro-apoptotic) or inhibit (anti-
apoptotic) apoptosis. The pro-apoptotic family members are further classified according 
to whether they contain multiple BH domains or BH3 only. The BH3-only proteins are 
pro-apoptotic and require the co-operation of their multidomain relatives to induce 
apoptosis (Kuwana, Newmeyer 2003). 
Anti-apoptotic proteins include: Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Al. These 
proteins act to protect the cell mitochondria against permeabilization by sequestration of 
pro-apoptotic proteins. All anti-apoptotic proteins contain some variation of BH1 and 
BH2 domain, however the proteins Bcl-2 and Bcl-xl contain all four (BH1-BH4) 
conserved domains (Levine et. al. 2008). The protein Bcl-2 acts to protect the 
mitochondria by binding to Bax and forming Bax/Bcl-2 heterodimers inhibiting the 
localization of Bax to the mitochondria and subsequently protecting against 
permeabilization of the outer mitochondrial membrane (Goping et. al. 1998). Also, anti-
apoptotic proteins such as Bcl-2 and Bcl-xl reside on the outer mitochondrial surface 
inhibiting mitochondrial membrane potential collapse caused by the pro-apoptotic 
proteins Bax and Bak (Levine et. al. 2008). 
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Pro-apoptotic proteins containing BH1-BH3 domains include: Bax, Bak and Bok. 
Bax and Bak have the ability to destabilize the mitochondrial membrane directly. Work 
by Wolter et. al 1997 showed that localization of GFP fused Bax from the cytosol to 
mitochondria is a crucial event during apoptosis leading to mitochondrial destabilization. 
Investigations by Kuwana et. al. 2002 showed that Bax in presence of Bid has the ability 
to form pores on the mitochondrial membrane directly, thus allowing the release of 
apoptogenic factors from the inter-mitochondrial membrane space. Furthermore, work by 
Shimizu et. al. 1999 suggests that Bax and Bak have the ability to interact with voltage 
dependent anionic channels (VDAC) on the mitochondrial membrane and thus 
permeabilize the mitochondrial membrane allowing molecules such as Cytochrome c to 
be released (figure l-3b). 
Other pro-apoptotic proteins contain only BH3 domain and are comprised of only 
alpha helix structure with no mitochondrial membrane binding domain, these include: 
Bad, Bid, Bik, Rk, BNIP3 and BimL (Kuwana Newmeyer 2003). BH3 only proteins are 
believed to play two distinct roles which are: localize pro-apoptotic proteins from 
cytosolic compartments to the mitochondrial membrane (Bid) and sequestering anti-
apoptotic proteins (Bad) (Levine et. al. 2008). The BH3 only peptides Bid and Bim 
activate Bax and Bak directly, whereas the Bad and Bik BH3 peptides act indirectly by 
inactivating Bcl-xL or Bcl-2, thus allowing Bax and Bak to act unopposed (Kuwana 
Newmeyer 2003). Therefore the pro-apoptotic mechanism primarily involves the 
destabilization of the mitochondrial membrane. 
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1.5 Mitochondria 
Mitochondria play an integral role in energy metabolism through oxidative 
phosphorylation, which generates energy in the form of ATP that is essential for the 
various biochemical reactions inside a cell (Leist et. al. 1997). Energy metabolism in the 
mitochondria involves reduction of O2 into H2O by electron transfer mechanisms through 
redox reaction in the electron transport chain. There are many internal factors within the 
mitochondria which when released activate the cellular processes involved in the 
induction of apoptosis. Therefore, mitochondria play a central role in both the intrinsic 
and extrinsic apoptotic pathways. The key outcome of both processes is induction of 
mitochondrial membrane collapse and release of the key mitochondrial apoptogenic 
factors such as Cytochrome c, AIF, and Smac/DIABLO (Green, Kroemer 2004, Yuan et. 
al. 2001 Kroemer, Reed 2000, Zoratti, Szabol997). 
As described earlier the release of the apoptogenic factors within the 
mitochondria is guided by one of two potential mechanism that lead to mitochondrial 
membrane potential (MMP) collapse. The first is by direct pore formation though the 
localization of pore forming pro-apoptotic proteins such as Bax and Bak (figure l-3a) 
(Green, Kroemer 2004) and the second is by opening of the mitochondrial protein 
transition pore complex. 
The opening of mitochondrial permeability transition pore complex (MPTP) is a 
crucial event in apoptosis. This complex includes the voltage dependent anionic channels 
(VDAC) which detects a change in mitochondrial membrane potential (A^m) and thus 
opens the MPTP complex allowing molecules of up to 5000 Daltons to pass through 
(Harris, Thompson 2000, Zoratti, Szabo 1997). Other integral components of the MPTP 
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include adenine nucleotide transporter (ANT), benzodiazepine receptor, hexokinase (HK) 
and cyclophillin D (figure l-3b). The MPTP complex can be opened directly through 
interaction with pro-apoptotic proteins such as Bax, partial failure of electron transport 
chain, cellular increases in reactive oxygen species and increases in the intra Ca 
concentrations (Zoratti, Szabo 1997). 
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Figure l-3a: Bax/Bak Mediated Mitochondrial Membrane Permeabilization 
Outer M itochondrial 
Membrane Bax/Hak Pore 





Figure l-3a: Bax/Bak mediated mitochondrial membrane permeabilization. Upon induction of 
apoptotic pathway, Bax and Bak migrate to the outer mitochondrial membrane where they homodimerize 
and form pores. This pore leads to the release of Cytochrome c, as well as other apoptogenic factors 
(Smac/DIABLO, AIF). 
Figure l-3b: Opening of the Permeability Transition Pore Complex Mediating 
Mitochondrial Membrane Permeabilization 
Outer Mitochondrial 
Membrane A




Figure 1 -3b: Opening of the permeability transition pore complex mediating mitochondrial 
membrane permeabilization. Upon induction of apoptotic pathway, BAX interacts with VDAC on the 
PTP where it leads to the opening of the PTP complex. Rapid in flow of H20 and ions leads to swelling of 
the mitochondrial matrix and rupture of the outer mitochondrial membrane releaseing apoptogenic factors 
such as cytochrome C, AIF and Smac/DIABLO. 
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1.5.1 Mitochondria in Cancer Therapy 
Cancer cells have devised mechanisms that inhibit mitochondrial dysfunction and 
prolong life of the cell in presence of various stresses. Recent advances in cancer research 
have uncovered key differences between cancer and normal cell mitochondria such as: 
mitochondrial membrane potential, metabolism, mitochondrial DNA mutations and 
mitochondrial integrity due to rapid cell division. It is therefore possible to exploit these 
key differences in cancer cell mitochondria to induce apoptosis in cancer cells 
selectively. 
A key difference in cancer cell metabolism over that of normal cells is the use of 
anaerobic metabolism as opposed to aerobic metabolism (Modica-Napolitano, Singh 
2002). This phenomenon has been named the "Warburg phenomena" where the reliance 
on anaerobic metabolism aids in the protection of cancer cells from mitochondrial 
induced apoptosis by reducing the risk of reactive oxygen species induced opening of the 
MPTP complex (Green, Kroemer 2004). Despite this phenomena, it has been observed 
that cancer cells have an increase in mitochondrial membrane potential (AYm) (Modica-
Napolitano, Singh 2002, 2004) as observed by localization of the cell membrane 
permeable cationic dye Rhl23. Experiments show that this dye accumulates in the 
mitochondria of cancers including: kidney, ovary, pancreas, lung, adrenal cortex, skin, 
breast, prostate, cervix, vulva, colon, liver and testis in greater extent then the normal cell 
counterparts (Don, Hogg 2004). The hydrophobic nature of the compound is believed to 
affect electron transport chain and ATP synthesis causing mitochondrial dysfunction. 
This result indicates that the increase in mitochondrial membrane potential in cancer cells 
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is driving the accumulation of the molecule into the mitochondria and also causing toxic 
effects specifically in cancer cells (Don, Hogg 2004). 
Mitochondrial DNA accounts for only 1% of expressed DNA inside a cell. 
However the expression of genes from mitochondrial transcript DNA (mtDNA) is 
imperative for normal cellular function (Modica-Napolitano, Singh 2004). Unlike 
mammalian DNA, mtDNA has no introns, and no protective histones. Furthermore, 
mtDNA is continuously exposed to oxidative stress due to oxidative phosphorylation 
reactions. Work by Selvanayagam et. al. 2004 revealed that mutations in mtDNA of 
NADH dehydrogenase subunit III is a phenotype associated with renal cell carcinoma. 
Rapid cell cycle progression due to over-expression of genes responsible for 
cellular growth is a phenomenon commonly observed in cancer cells. Due to this 
occurrence, additional mitochondrial differences have been observed in cancer cells when 
compared to normal cell mitochondria. It was recently postulated that cancer cell 
mitochondria are unable to properly ensure proper formation of mitochondrial membrane 
components during mitosis (Modica-Napolitano, Singh 2002, 2004). This lack of proper 
mitochondrial replication during mitosis has the potential to cause the development of 
mitochondria with altered inner and outer mitochondrial membrane compositions (Villa, 
Doglia-2004). 
These differences between cancer and normal cell mitochondria have the potential 
to give rise to novel targets for chemotherapeutics research. A new class of compounds 
termed "mitocans" has been proposed which have the ability to exploit the vulnerability 
of cancer cell mitochondria (Neuzil et. al. 2007). Vitamin E analogues have recently 
shown promise to target cancer cell mitochondria. One such compound which shows 
18 
selectivity in inducing apoptosis through mitochondrial destabilization in cancer cells at 
concentrations that is tolerated by normal cells is the vitamin E analogue a-tocopheryl 
succinate (Neuzil et. al. 2007). Another compound, lonidamine, has been shown to cause 
opening of the mitochondrial transition pore complex through binding to the adnenine 
nucleotide transporter site (Neuzil et. al. 2007). Therefore the mitochondria can provide 
novel targets for selective apoptosis induction (Kroemer 2003). 
1.6 Current Chemotherapy Options 
Current cancer treatment strategies depend on the severity of the disease. Upon 
diagnosis of cancer, the treatment methods available include systemic and local 
intervention. New techniques and compounds have lead to prolonged life and sometimes 
complete inhibition of cancer re-occurrence. Unfortunately no cure exists and drugs used 
as chemotherapies can have drastic side effects which in turn have the potential to do 
more harm then good to the patient. 
Local therapies include surgical intervention and ionizing radiation (IR). Removal 
of the cancerous growth is accomplished by surgical intervention along with 
supplemental drugs to prevent reoccurrence of the disease. Radiation therapy is given to 
approximately 70% of cancer patients (Martin 2001). This treatment involves inducing 
oxidative stress leading to DNA damage on cancerous tissue through focused beams of 
ionizing radiation (Jeremic 2004). Unfortunately the ionizing beam of radiation also 
affects nearby normal cells, increasing the probability of DNA damage in normal tissue 
potentially leading to formation of secondary tumors (Zhang et. al. 2001). 
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Nearly 50% of all newly diagnosed cancer patients will receive some form of 
systemic chemotherapy (Martin 2001). Systemic therapies vary in the way that they 
target a particular cancer cell however the overall desired effect of these therapies 
remains the inhibition of growth and the induction of apoptosis. These therapies work 
simply by the fact that cancer cells divide rapidly and therefore are more vulnerable to 
stresses that are imposed to replication machineries. Specific targets of systemic therapies 
include: cell surface receptors, hormonal receptors, DNA, and cell cycle machinery. 
Immunotherapy's act on specific protein targets on the cancer cell membrane. 
They induce immunological responses and activate internal cellular processes that lead to 
apoptosis. This type of chemotherapeutic strategy is used in the treatment of breast and 
leukemic cancers (Kim 2005). One such immunotherapy named Trastuzumab is a 
monoclonal antibody therapy which targets breast cancers that expresses HER-2 which is 
an epidermal growth factor responsible for cellular growth (Duffy 2005). Once bounded 
to HER-2 Trasuzumab causes down modulation of HER-2 leading to: cell cycle arrest 
through p27, immune response, and inhibition of angiogenesis (Duffy 2005). 
Unfortunately, treatment with Trasuzumab is limited to cancers expressing HER-2 and 
current research indicates that even when HER-2 expression is high the effect of 
Trasuzumab is limited to the duration of therapy (Albanell, Baselga 2001). 
Hormonal therapies include a class of drugs termed Selective Receptor 
Modulators (SRM's). These compounds are selective for certain types of breast, ovarian 
and thyroid cancers which exhibit specific cellular receptors (Kleinsmith 2006). 
Tamoxifen is the prototypic SRM, which acts antagonistically on the estrogen receptor 
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(Smith et. al. 2004). Estrogen receptor as previously mentioned is a transcription factor 
involved in expressing proteins critical for maintaining cell growth and survival (Shao, 
Brown 2003). Therefore the antagonistic effect of Tamoxifen acts by sequestering the 
estrogen receptor so that it cannot bind to estrogen and therefore cutting off vital receptor 
mediated growth mechanisms. The benefit of this therapy is that it is selective only 
towards cells that exhibit estrogen receptor and therefore has little toxic effects towards 
normal cells. However, the downside is that it is limited to cancers expressing the 
estrogen receptor. 
Cell cycle inhibitory drugs act by reducing the rate of mitosis thereby leading to 
apoptosis. The class of drugs called Taxanes, isolated from the pacific yew tree, works in 
such a way. In particular, one such compound called Taxol, acts to induce apoptosis by 
microtubule stabilization during mitosis. Taxol binds to pockets in P-Tubulin inhibiting 
GTP hydrolysis of the other side of the polymer (Yeung et. al. 1999). Inhibition of 
microtubule depolymerization in G2-M phase leads to bcl-2 phosphorylation which 
inhibits bcl-2's normal anti-apoptotic activity, therefore leading to apoptosis (Yeung et. 
al. 1999). Unfortunately, taxol is non-specific and exhibits toxicity to normal cells 
leading to drastic side-effects to the patient. For this reason selective targeting of cancer 
cells is a priority in novel therapeutic strategies in cancer therapy research. 
1.7 Pancratistatin and Tamoxifen 
The vast amount of research in cancer therapeutics has given rise to many 
compounds which target many biochemical processes in cancer cells. All the research in 
such compounds have made great strides in therapeutic options to patients, however the 
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limitations of each individual treatment remains with respect to unwanted and drastic side 
effects. Therefore, the current focus is in the development of compounds which are toxic 
and selective towards cancer cells. 
Previous investigations with Tamoxifen (figure l-4a) have established the 
antagonistic action of this drug on the estrogen receptor. Current advances in Tamoxifen 
research have shown that it plays roles outside the normal estrogen receptor antagonism, 
which induces apoptosis in ER+ cancer cells. Tamoxifen induced apoptosis involves 
biochemical pathways involving: Protein kinase C induced apoptosis, binding to 
calmodulin, induction of c-Myc, mitogen activated protein kinases (MAPK) and 
mitochondrial dysfunction (Mandlekar, Kong 2001). In particular, work by Moreire et. al. 
2006, has shown that Tamoxifen has binding affinity to complex 1 of the electron 
transport chain, which in turn causes destabilization of mitochondrial membrane potential 
and increases levels of reactive oxygen species. Also, work done by Kallio et. al. 2005, 
showed that MCF-7 (mammary adenocarcinoma) cells treated with 5-7uM Tamoxifen in 
serum free media exhibited mitochondrial dysfunction, reactive oxygen species increases 
and Cytochrome c release. 
There is a clear link between consumption of natural compounds and decreased 
susceptibility to disease. Epidemiological research has proven that consumption of 
phytochemicals from fruits and vegetables results in reduced risk of cancer development 
over the lifetime of an individual (Reedy et. al. 1997). Therefore, isolating natural 
substances which show promise as anti-cancer compounds, is an approach used by many 
researchers and has thus opened the window to current chemotherapeutics (taxol) and 
future promising compounds (pancratistatin). 
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Pancratistatin (figurel-4b) is a natural compound that was originally isolated 
from the spider lily Pancratium Litorale in 1993 by Pettit et. al. Early work with PST 
revealed the potential to act as an anti-neoplastic and anti-fungal agent (Luduena et. al. 
1992). Pharmacological work with PST has been limited due to the low yield obtained 
from extraction of this compound from the spider-lily, therefore, surprisingly little in-vivo 
and in-vitro work has been completed in PST related research. Previous results from our 
lab demonstrated the ability of PST to induce apoptosis in cancer cells (McLachlan et. al. 
2005). Importantly, the effects of PST induced apoptosis were found to be selective 
towards cancer cells and having no toxic effects towards normal cell lines. (McLachlan 
et. al. 2005). The exact biochemical mechanism of action in PST induced apoptosis is 
unknown, however recent advances in our lab demonstrate that this drug has potential 
targets existing directly on the mitochondria of cancer cells leading to selective induction 
of apoptosis. Therefore, research is currently being undertaken in our lab to exploit this 
feature of cancer selectivity, and understand the mechanism of how this phenomenon 
occurs. 
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Figure 1 -4a: Chemical structure of tamoxifen citrate 
Tamoxifen citrate (C32H37NO8) has a molecular weight of 563.32g/mol. The molecular structure is shown 
here 













Figure l-4b: Chemical structure of pancratistatin 
Pancratistatin (C14Hi5NOg) has a molecular weight of 325.28g/mol. The molecular structure is shown here. 
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1.8 Objectives 
The present study expands upon the previous work completed on PST which 
established this compound as a selective inducer in apoptosis by targeting the 
mitochondria. The objectives of this investigation include: 
1. Study combinatorial treatment of cancer cells with PST and Tamoxifen in both ER 
negative and ER positive breast cancer cells as well as determine the level of toxicity to 
normal cells in-vitro. 
2. Investigate biochemical features in PST induced apoptosis in both Hs578-T and MCF-
7 cell lines in order to gain key insights into the biochemical mechanism induced by PST 
treatment. 
3. Establish a mouse breast cancer model in order to investigate the in-vivo response of 
PST and Tamoxifen treatment. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell Culture 
2.1.1 Cell lines 
Normal human fibroblast (NHF) cells (AG09309) were obtained from Coriell 
Institute for Medical Research, Camden, NJ, USA. Mammary gland adenocarcinoma 
(MCF-7) cells were obtained as a gift from Dr. Hubberstey and Dr. Porter, University of 
Windsor as well as purchased from American Type Culture Collection (ATCC). 
Mammary gland carcinoma (Hs-578T) cells were obtained from the American Type 
Culture Collection (ATCC), Manassas, VA, USA. 
2.1.2 Media and Supplements 
Dulbecco's modified Eagle's medium (DMEM) / nutrient mixture Ham's F-12 
medium modified with 2 mM L-glutamine obtained from Sigma Chemical Company, 
Mississauga, Ontario, Canada. L-Glutamine and Gentamycin were purchased from 
Invitrogen Canada Inc., Burlington, Ontario, Canada. Fetal bovine serum (FBS), glucose, 
bovine insulin, sodium bicarbonate and sodium pyruvate were purchased from Sigma 
Chemical Company, Mississauga, Ontario, Canada. 
2.2 Pancratistatin and Tamoxifen 
Pancratistatin (PST) was obtained from our collaborator, Dr. James McNulty, 
McMaster University, Hamilton, Ontario, Canada. PST was isolated from the bulb of the 
Hymenocallis littoralis, a spider lily native to the islands of Hawaii, following a previously 
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published method (Pettit et al. 1993). Tamoxifen Citrate was purchased from Sigma Chemical 
Company, Mississauga, Ontario, Canada. 
2.3 Antibodies 
Monoclonal primary antibodies raised in mouse were purchased from Sigma Chemical 
Company, Mississauga, Ontario, Canada these consisted of: anti-Bax, anti-Bcl-xl and anti-Bcl-2. 
Polyclonal primary antibodies raised in rabbit were purchased from Sigma Chemical Company, 
Mississauga, Ontario, Canada and consisted of: anti-Actin and anti-Bad. Furthermore polyclonal 
primary raised in rabbit anti-Succinate Dehydrogenase B and monoclonal primary raised in 
mouse anti-Cytochrome c antibodies were purchased from Santa-Cruz Biotechnology Inc., Santa-
Cruz, CA. Secondary anti-rabbit and secondary anti-mouse conjugated antibodies to HRP were 
purchased from Sigma Chemical Company, Mississauga, Ontario, Canada. 
2.4 Apparatus and Instrumentation 
The Leica DM IRB fluorescent microscope was obtained from Lieca, Wetziar 
Germany. The multi-well plate reader, Spectra Max Gemini XS, was obtained from 
Molecular Devices, Sunnyvale, California and the UV-Visible Spectrophotometer was 
purchased from Thermo Technologies. Chemi-Imager v5.5 (Alphatech Inovations) was 
used to visualize westernblots. A Becton Dickinson FACSCalibur flow cytometer was 
used at Wayne State University. 
Cell culture was conducted under sterile conditions in a class-II type A/B3 
Biosafety cabinet (NuAire Inc., Plymouth, MN, USA), and all cultures were maintained 
in a CO2 incubator containing a HEPA filter (Thermo Forma Scientific, Inc, Marietta, 
OH, USA) 
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Centrifugation was conducted using a low speed Jouan CR3-I centrifuge (Jouan by 
Thermo Electron Corporation, Waltham, MA, USA) and a MC2 DESAGA centrifuge 
(Sarstedt-Gruppe, Montreal, Quebec). Other general laboratory equipment included the 
following: a pH Meter (VWR, Model 8100) with buffer solutions from VWR, Adventurer 
balance (OHAUS, Ontario, Canada), Vortex Jr. Mixer from Scientific Industries Inc, 1296-002 
DELFIA plate shaker from Wallac, Rocking platform model 200 from VWR, and Corning 
stirrer from Fisher Scientific. Additionally, a Dounce homogenizer from Kontes Glass 
Company (NJ, USA), freezer vials (VWR), and Eppendorf pipettes (Fisher Scientific) were 
used. 
2.5 In-vitro Proliferation of Cell Lines 
MCF-7 cells were grown at 37°C and 5% C02 in DMEM / Nutrient Mixture 
Ham's F-12 medium modified to contain 2mM L-glutamine, 1.5g/L sodium bicarbonate, 
and lOmg/mL Gentamycin supplemented with 10% fetal bovine serum (FBS). 
NHF cells were grown at 37°C and 5% C02 in DMEM modified to contain 2mM 
L-glutamine, 1.5g/L sodium bicarbonate and lOmg/L Gentamycin supplemented with 
15% FBS, IX essential and IX non-essential amino acids, and IX vitamins. 
Hs578-T cells were grown at 37°C and 5% C02 in DMEM with 4 mM L-
glutamine adjusted to contain 1.5g/L sodium bicarbonate, lOmg/L Gentamycin, and 
4.5g/L glucose supplemented with O.Olmg/mL bovine insulin and 10% fetal bovine 
serum 
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2.6 Sub-culturing of Cells 
Cells were sub-cultured by removing the culture medium by aspiration and 
rinsing the cells with a 0.25% (w/v) trypsin - 0.53mM EDTA solution or Puck's solution 
(140mM NaCl, 5mM KC1, 5.5mM glucose, 4mM NaHC03, 0.8mM ethylenediamine 
tetraacetic acid (EDTA)) in order to remove all traces of serum (serum contains a trypsin 
inhibitor). Additional 20% (w/v) trypsin solution was added and the cells were incubated 
at 37°C until the cell layer began to disperse (usually within 5 to 10 minutes). Additional 
appropriate complete media was added, cells were aspirated, and appropriate aliquots of 
the cell suspension were added to new culture flasks or plates. 
2.7 Treatment of Cells with Anti-Cancer Drugs: PST and Tamoxifen 
Cells were grown to 70% confluence and treated with the indicated concentration of 
Pancratistatin (PST) and Tamoxifen by the addition directly to fresh complete medium for 
varying time periods. 
2.8 Data Collection and Analysis 
All fluorescent and phase contrast pictures were taken using Improvision's OpenLab 
3.1.5 Software on a Leica DM IRB fluorescent microscope. All pictures were processed using 
Adobe Photoshop software and Microsoft Powerpoint software. Fluorescence measurements 
were collected using SoftMax PRO 3.1.2 software and a SpectraMax Gemini XS fluorescent 
plate reader. Microsoft Excel software was used for data representation and statistical analysis. 
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2.9 Nuclear Staining and Phase Microscopy 
In order to examine nuclear morphological changes induced by treatment of PST 
and Tamoxifen, cancerous and non-cancerous cells were grown and treated with PST and 
Tamoxifen, followed by staining with lOuM of Hoechst-33342 (Sigma Chemical 
Company, Mississauga, Ontario, Canada). The fluorescent dye was directly added to the 
culture media at a final concentration of luM and incubated for 10 minutes. Cells were 
examined under a fluorescent microscope and phase contrast and fluorescence pictures 
were taken. 
2.10 Trypan Blue Staining 
The Trypan blue exclusion test (Sigma Chemical Company, Mississauga, Ontario, 
Canada) is a common method to measure the number of viable cells in a given sample. 
Cells were trypsinized as previously described, except that floating cells were spun down 
and added to the cell suspension. Fresh media was added and lOuL of the cell suspension 
was added to lOuL of 0.4% Trypan blue stain. Cells were counted using a 
hemacytometer and the number of cells per volume unit of sample was calculated. 
2.11 Flow Cytometry Analysis 
Flow cytometry was carried out at Wayne State University by a trained specialist 
(Dr. Kim Zukowski). A Becton Dickinson FACSCalibur equipped with two lasers: a 
standard Argon laser at 488 nm and a red diode laser at 635 run which measures forward 
scatter (cell size) and side scatter (granularity, complexity). The FACSCalibur is 
controlled by a FACStation which consists of a Macintosh Power PC 7600 loaded with 
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Becton Dickinson Immunocytometry Systems acquisition and analysis software including 
CellQuest, ModFit, FACSComp, FACSConvert, Attractors, and Paint-A-Gate. Cells were 
analyzed for annexin binding and tunnel labeling. 
2.11.1 Annexin-V Binding Assay 
The cells were grown and treated with varying combination of drugs (PST and 
Tamoxifen). After various treatment times, an annexin-V binding assay (Sigma Chemical 
Company, Mississauga, Ontario, Canada) was conducted using a purchased kit and the 
manufacturer's protocol. Cells were harvested via trypsinization, washed twice using 
phosphate buffer saline (PBS) (0.137mM NaCl, 2.7mM KC1, 8.0mM Na2HP04, 1.47mM 
KF^PCv) and then re-suspended in annexin-V binding buffer (lOmM HEPES and NaOH 
pH 7.5, 140mM NaCl, 2.5mM CaCl2) at a concentration of -10
 6 cells/mL. IOOUL of 
each solution was transferred to eppendorf tubes, 5uL of annexin-V-FITC conjugate was 
added, and the mixture was incubated for 15 minutes at room temperature. After 
incubation, the cells were re-suspended in 400[j,L of fresh binding buffer. Cells were then 
put into eppendorfs and taken to Wayne State for flow cytometry analysis. 
2.11.2 TUNEL Assay 
In order to observe DNA fragmentation, an APO-BrdU Tunel (terminal urdine-
derivatized nick end labeling) assay was preformed using the manufacturer's protocol 
(Sigma Chemical Company, Mississauga, Ontario, Canada). Cells were grown and 
treated as previously described. Approximatly ~lxl06 cells were washed with PBS and 
incubated in 5mL of 1% (w/v) paraformaldehyde in PBS on ice for 15 minutes. The cells 
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were washed twice with PBS and re-suspended in 0.5mL of PBS. Cells were added to 
5mL of ice-cold 70% (v/v) ethanol and set at -20°C overnight (at least 12 hours). 
The next day, ethanol was removed by centrifugation and washed twice using the 
wash buffer, provided in the kit. 50uL of DNA labeling solution was prepared for each 
sample (lOuL of reaction buffer, 0.75uL of TdT enzyme, 8.0uL of BrdUTP and 31.25uL 
of dH20) and cells were incubated for 60minutes in DNA labeling solution at 37°C in a 
temperature controlled bath (shaken every 15 minutes). At the end of the incubation 
time, 1 .OmL of Rinse Buffer (provided in the kit) was added to each tube followed by 
centrifugation. The cells were washed twice with Rinse Buffer and incubated in lOOuL 
of antibody staining solution (5uL Alexa Fluor 488 dye labeled anti-BrdU antibody, 
95 uL Rinse Buffer) for 30minutes at room temperature. The samples were then re-
suspended in a total volume of 400uL (rinse buffer) put in eppendorf tubes and taken for 
flow cytometry analysis. 
2.12 Total and Cytosolic Cell Lysate 
Cells were harvested by mechanical dislodging using a rubber policeman and 
centrifuged at 500xg for 5 minutes. The supernatant was removed and the pellet was 
washed twice with IX PBS pH 7.4 and centrifuged again at 500xg for 5 minutes. The 
supernatant was removed and the pellet was re-suspended in 0.4 ml of extraction buffer 
(25mM HEPES pH 7.25, 5mM MgCl2, lmM EGTA, 0.1% Triton X 100). The cell 
suspension buffer was transferred into a Dounce cell homogenizer. Cells were 
homogenized with -20 strokes to produce the total cell lysate. Cytosolic cell lysates 
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were obtained by an additional centrifugation at 200xg. The supernatant was collected as 
the cytosolic cell lysate. 
2.13 Mitochondrial Isolation 
Intact mitochondria were isolated from cells using a previously published method 
(Li et. al. 2003). Cells were collected by centrifugation at 500xg for 5 minutes. The pellet 
was washed twice with ice cold PBS and centrifuged at 250xg. The pellet was re-
suspended in isolation buffer containing ImM EDTA, lOmM HEPES (pH 7.4) and 
250mM sucrose. Cells were homogenized and the disrupted cells were centrifuged for 5 
minutes at 600xg at 4°C. The supernatant was collected and centrifuged at 15 OOOxg at 
4°C for 5 minutes and the resulting pellet was considered to be crude mitochondria. The 
pellet was re-suspended in isolation buffer without EDTA. Mitochondrial suspensions 
were kept on ice and all of the experiments were performed within 2 hours of 
centrifugation. 
2.14 ROS Detection in Isolated Mitochondria 
Isolated mitochondria from untreated cells were subjected to direct incubation 
with 0.5 uM PST and 5uM Tamoxifen. Also, lOOuM paraquate was added to 
mitochondrial preparations as a positive control. Mitochondrial ROS generation was 
measured using Amplex Red dye (Sigma Chemical Company, Mississauga, Ontario, 
Canada), increase in the fluorescence due to oxidized Amplex Red fluorescence was 
approximated to be due to mitochondrial destabilization. This assay utilized horseradish 
peroxidase (HRP) to couple Amplex Red oxidation with peroxide reduction. In a 96-well 
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micro-titer plate, 0.25mg of mitochondrial suspension was added to a lOOul reaction 
mixture containing 0.25M sucrose, ImM MgCl2, lOmM HEPES, lOOmM succinate, 5uM 
Amplex Red and 1 unit of HRP per well. Fluorescence of oxidized Amplex Red was 
measured at excitation 560nm and emission 590nm using the Spectra Max Gemini XS 
which was set to read the wells every 2 min over a total time of 2 hours. 
2.15 Whole Cell ROS 
Cells were grown on 24-well clear bottom plates until 70% confluence was 
established. Cells were treated with varying concentrations of drugs mentioned (PST and 
Tamoxifen) and incubated for a period of 48 hrs. Following incubation, lOuM T-T-
dichlorofluorescin diacetate (H2DCFCA; Molecular Probes, Eugene, OR) was added to 
each well and cells were monitored overnight for 18 hrs with readings taken in 10 min 
intervals using SoftMax PRO 3.1.2 software on a SpectraMax Gemini XS fluorescent 
plate reader at excitation 495nm and emission 530nm. Microsoft Excel software was used 
for data representation and statistical analysis. 
2.16 Western Blot 
2.16.1 Protein Estimation 
The concentration of proteins present in cytosolic or mitochondrial cell lysate 
samples was estimated using a protocol from BioRad Laboratories. Protein estimation 
was conducted by adding lOuL aliquots of each cell lysate sample, 790 oL of water and 
200uL of BioRad protein assay reagent into lmL plastic cuvettes. The mixtures were 
vortexed and allowed to stand for 10 minutes at room temperature. The absorbance was 
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then measured a UV-Visible Spectrophotometer and analyzed at 595 run. A standard 
curve was prepared by using various amounts of a standard protein solution (lmg/ml 
bovine serum albumin). 
2.16.2 SDS-PAGE and Gel Transfer 
Protein samples were separated using either 10% or 12% SDS-PAGE (sodium 
dodecyl sulphate polyacrylamide gel electrophoresis). A total of 40 ug of protein was 
loaded into the gel and run in running buffer (1.44g Glycerine,0.1g SDS, 0.3g Tris-HCl 
in 1L of distilled water, pH=8.9 ) for one hour at a constant 30 mAmps and 200V. The 
gel was then transferred to a nitrocellulose membrane in transfer buffer (20% methanol, 
25mM Tris Base, 0.2M Glycine, pH<8) for one hour at 200mAmps and 80V. The 
membrane was then stained with Ponceau S for rapid reversible detection of protein 
loaded and an image was scanned. 
2.16.3 Immunoblotting Analysis 
The membrane was blocked in 5% milk in TBST for one hour at 25°C. The 
membrane was then incubated with primary antibody solution (2% milk in TBST, 1:1000 
dilution) and incubated for one hour. Then the membrane was washed 3 times with TBST 
for 15 min. The membrane was then incubated for one hour with secondary antibody (2% 
milk in TBST and a 1:1000 dilution) consisting of anti-mouse conjugated to HRP or anti-
rabbit conjugated HRP. As before, the membrane was subjected to three 15 minute TBST 
washes. The chemiluminescent peroxidise substrate reagent and buffer (Sigma Chemical 
Company, Mississauga, Ontario, Canada) was prepared and the blot was visualized using the 
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Chemi-Imager v5.5 (Alphatech Inovations) in Dr. Ananvoranich's lab. Spot analyses was 
carried out using image J software downloaded directly from the internet. 
2.17 Whole Cell Caspase-8 Activation Assay 
Whole cell caspase-8 detection assay was purchased from Cell Technology Inc. 
Mountain View, CA. As per protocol, treated and un-treated cells were placed in 96 well 
black fluorescent plates in 300uL of media. A total of lOuL of the 30 X caspase detection 
reagents (FAM-LETD-FMK) was added directly to 300uL of cell suspension. Cells were 
incubated for 1 hour at 37°C. After the incubation time the media was decanted by 
spinning the plates in a centrifuge and gently flicking the plate. Approximately 300uL of 
IX Wash Buffer (provided in kit) was added to each well, centrifuged and removed. 
After the final wash lOOuL of Wash Buffer was added at which point the plate was ready 
for analysis. The plate was read using a fluoriometer at an excitation of 515nm and 
emission of 590nm. 
2.18 Long-term Drug Resistance and Viability Study 
MCF-7 breast cancer cells were grown and maintained using sub-culturing 
techniques, however, 25nM and 50nM PST was added to the media after each culture 
splitting for a period of 20 days. After 20 days of 25nM and 50nM PST treatment the 
cells were treated with luM PST for 72 hours. At this time luM Hoechst 33342 dye was 
added to observe positive nuclear staining as mentioned before. 
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2.19 JC-1 Staining 
Mitochondrial membrane permeability was visualized using 5,5' ,6,6'-tetrachloro-
1,1' ,3,3' -tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye purchased from Sigma 
Chemical Company, Mississauga, Ontario, Canada and used according to the 
manufacturer's protocol and a previously published method (Olichon et. al. 2003). The 
cells were grown and treated as previously described. The cells were incubated in media 
containing luM of JC-1 dye for 15 minutes and the media was replaced by PBS (floating 
cells were re-added after centrifugation). The cells were examined under a fluorescent 
microscope and pictures were taken. 
2.20 In- vivo Treatment Preparation 
Intraperitoneal Placebo treatment consisted of 250uL of sterile peanut oil. PST 
treatments were intratumoural and consisted of 5uL of lOmM PST stock solution in a 
total volume of 250uL of sterile PBS this was calculated to be approximately 3mg/kg 
concentration. Tamoxifen treatments consisted of 20uL of lOmM Tamoxifen stock added 
to 250uM steril peanut oil, which was calculated to be approximately 25mg/kg. Peanut 
oil was used based on previously published method of Tamoxifen injection (Paine-
Murrietta et. al. 1997). 
2.21 RAG 2M Mouse Care, Xenograft Transplantation and Treatment 
For this study, a total of 10 male immunodeficient RAG 2M mice were purchased 
from Taconic, Cambridge City, IN. Mice were injected with 60 day slow release 17p-
estradiol pellets using a trochar device, both purchased from Innovative Research of 
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America, Sarasota, FL. The mice were housed in autoclaved cages and fed irradiated 
food and autoclaved water. All of the mice were injected sub-cutaneously with 6 x 106 
human MCF-7 breast cancer cells and visible tumours formed after 10-14 days. The mice 
were then divided into 4 groups: 3 received intraperitoneal Placebo treatment; 2 received 
intratumoral PST treatment; 3 received intraperitonial Tamoxifen treatment; and 2 
received intratumoural PST + intraperitonial Tamoxifen treatment. The PST treated mice 
were given approximately 3mg/kg PST twice weekly and Tamoxifen treated mice were 
given 25 mg/kg Tamoxifen 3 times a week for 5 weeks. Periodically, the mice were 
weighed and the tumour volume was measured using callipers. One week after the last 
treatment, all mice were sacrificed by CO2 asphyxiation according to ethical care 
committee protocol. 
2.22 Tissue Preparation for Histochemical Analysis 
The tissues stored in 10% formalin were moved to 70% ethanol within 24hours 
and then processed through a dehydration gradient being put into paraffin-wax blocks. 
The tissues were moved through an increasing ethanol gradient and then submerged in 
xylene and wax. The following times and concentrations were used: 70% EtOH 
overnight; 1 hour 95% EtOH; 1 hour absolute EtOH; 90 minutes xylene; 1 hour 
xylene/wax (50:50); wax overnight at 60°C. Wax blocks were assembled by placing a 
piece of tumour, liver and kidney from one mouse at the bottom of the mould and then 
pouring wax to fill the mould. The mould is then placed in -20°C overnight before it is 
ready to be sectioned using a microtome. Microtome sections of 8 microns were cut into 
ribbons, which were laid in a 40°C water bath and allowed to stretch out before being 
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mounted on a superfrost slide. About 3-4 sections were placed on each slide. The slides 
were left overnight on a hot plate at about 55°C. The slides were then ready for 
histochemical analysis. 
2.23 Tissue Preparation Revision 
When the tissues were prepared and sectioned, it was found that the liver tissues 
were over dehydrated. The dehydration of the tissues is irreversible, thus the protocol was 
optimized for future work. The revised method is identical to the previous method but the 
tissue is subjected to a shorter time in xylene to reduce the amount of dehydration caused 
to the tissues. The optimum xylene incubation time was found to be 30 minutes compared 
to the 90 minute incubation in the previous method. 
2.24 TUNEL Assay With DAPI on Tissue Sections 
The Terminal uridine deoxynucleotidyl transferase dUTP Nick End Labelling 
(TUNEL) assay was purchased from Sigma Chemical Company Mississauga Ontario . 
This assay detects the presence of nicks in the DNA which can be identified by terminal 
deoxynucleotidyl transferase, an enzyme that catalyzes the addition of dUTPs that are 
secondarily labelled with a marker. These nicks are typically observed in cells that have 
undergone apoptosis. DAPI (4',6-diamidino-2-phenylindole) is a fluorescent stain that 
intercalates into the minor groove of DNA. Chromatin condensation is consistent with 
apoptosis and can be visualized by a concentrated and brighter fluorescence than the 
surrounding non-apoptotic nuclei. 
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This assay begins with the slide being rehydrated according to the following 
procedure: 2x5 min xylene; 2x5min absolute EtOH; 3 min 95% EtOH; 3 min 80% EtOH; 
3 min 70% EtOH; 3 min H2O; 3 min PBS. The slides were incubated in primary antibody 
solution (40uL Reaction buffer, 3uL TdT enzyme, 24uL BrdUTP, 125uL dH20) 
overnight at 4°C. The slides were then washed with Rinse Buffer and incubated in Alexa 
Fluor 488 secondary antibody solution (lOuL Alexa Fluor, 190uL Rinse Buffer) for 1 
hour at 25°C. The slides were then washed with PBS and mounted using mounting media 
containing DAPI nuclear stain. 
2.25 Haematoxylin and Eosin 
This stain is performed to visualize the morphology of the tissue. The nucleus stains 
blue and the cytoplasm stains pink, which gives an overall morphological view of the 
tissue. The slides were dewaxed/rehydrated, stained with Harris Haematoxylin (Fischer 
Scientific, Kalamazoo MI), dehydrated, and then stained with Eosin Y (EMD Chemicals 
Inc., Darmstadt Germany) according to the following procedure: 10 min xylene; 10 min 
absolute EtOH; 5 min 95% EtOH; 5 min 70% EtOH; dipped in 50% EtOH; dipped in 
30% EtOH; dipped in H2O; 3 min Haematoxylin stain; dipped in H2O; dipped in 30% 
EtOH; dipped in 50% EtOH; dipped in 70% EtOH; dipped in 95% EtOH; 3 min Eosin 
stain: 10 min absolute EtOH; 10 min xylene. These last two steps are done to completely 
dehydrate the tissues. The slides were then mounted with coverslips using Cytoseal 60 
and viewed on a light microscope. 
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2.26 Tissue Preparation for Biochemical Analysis 
The flash-frozen tissue samples were unfrozen at 4°C and homogenized in 3 
volumes of homogenization buffer (50mM Tris-HCl, 150mM Nail, ImM EDTA, ImM 
PMSF, ImM benzamidine, lOug/ml pepstatin A and lOug/ml leupeptin, 2% beta 
mercaptoethanol) using a Sorvall Omni-Mixer at 4°C.15 The samples were centrifuged at 
2700 x g for 1 Omin at 4°C to separate the nuclear and cell debris from the supernatant. 
The supernatant was then centrifuged at 10,000xg for 10 minutes at 4°C to obtain the 
mitochondrial pellet and the post-mitochondrial cytoplasmic supernatant. The 
mitochondrial pellet was resuspended in the homogenisation buffer; both fractions were 
used for biochemical analysis using western blot procedure. 
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CHAPTER 3: RESULTS 
3.1: In-vitro Apoptotic Synergy Exhibited by PST and Tamoxifen 
Pancratistatin has been shown to have the ability of activating apoptosis in cancer 
cells specifically through the destabilization of cancer cell mitochondria. Tamoxifen 
which is primarily an anti-estrogen treatment for breast cancer, has recently been 
discovered to induce apoptosis through biochemical pathways unrelated to the estrogen 
receptor (Mandlekar, Kong 2001). The electron transport chain of cancer cell 
mitochondria has been found to be disrupted by Tamoxifen through binding of 
Tamoxifen to the flavomononucleotide binding site in complex 1 (Moreira et. al. 2006). 
Due to these observations PST and Tamoxifen were considered as a potential 
combination therapy in both estrogen receptor +/- breast cancers. 
3.1.1 Susceptibility of MCF-7 Cells to Apoptosis by PST Treatment 
Several cancer cell lines are susceptible to PST-induced apoptosis at luM 
concentration including: Jurkat (B-cell lymphoma), SHSY-5Y (neuroblastoma), 5123 (rat 
hepatoma) as reported by our laboratory (Pandey et. al. 2001, McLachlan et. al. 2005). 
Furthermore, we have shown that PST specifically induces apoptosis in cancer cells with 
minimal effect on normal cell lines (McLachlan et. al. 2005). 
To evaluate the effect of PST on estrogen dependent breast cancer cells, we 
treated MCF-7 (adenocarcinoma) with concentrations of luM and 500nM PST for a 
period of 72 hours. Following treatment we stained the cells with cell permeable Hoechst 
33342 dye to semi-quantitatively determine the number of cells exhibiting the hallmark 
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feature of apoptosis: nuclear condensation. Figure 3-1 shows that 0.5uM PST 
concentration caused approximately 45% apoptosis at 72 hours and 1 uM PST at this time 
point caused 60% apoptosis in MCF-7 cells. 
3.1.2 Synergistic Action of PST and Tamoxifen in ER+ MCF-7 Cells 
Research from as early as the 1970's shows that 50-70% of invasive breast cancer 
expresses estrogen receptor, based on pooled analysis of 400 patients (McGuire et. al. 
1975). Of these estrogen receptor positive breast cancer patients 50-60% responded well 
to endocrine therapy (McGuire et. al. 1975). Tamoxifen as a therapy has selectivity for 
the estrogen receptor and therefore shows little toxicity to normal cells (Duffy 2005). 
This initially sparked our interest in examining combinatorial therapy of Tamoxifen and 
PST on estrogen receptor positive breast cancer (MCF-7). We aimed to determine the 
effect of adding PST and Tamoxifen in combination to the estrogen receptor positive 
MCF-7 cell line to evaluate the apoptotic response to combination therapy relative to 
each compound separately. 
Breast adenocarcinoma positive for ER was treated with Tamoxifen at luM, 
5uM, and 10|_iM concentrations for 72 hours and stained with Hoechst 33342 dye to 
generate relative apoptotic indices. As shown in figure 3-1 and 3-2a 5uM Tamoxifen 
treatment did not cause apoptosis as compared to control; only the higher concentration 
of lOuM Tamoxifen causes significant apoptosis in this cell line. We then treated MCF-7 
cells with low dose of 0.5uM PST in combination with luM, 5uM and 10|j,M Tamoxifen 
and the effective dose of luM PST in combination with 1, 5, lOuM Tamoxifen for a 
period of 72 hours. Figure 3-2b shows the result of combinatorial treatment of 5uM 
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Tamoxifen and luM PST after 72 hours: a significant increase in apoptosis is evident 
when compared to Tamoxifen and PST on their own (figure 3-1). The apoptotic index of 
combined treatment of luM PST and 5uM Tamoxifen increased by approximately 20% 
when compared to luM PST alone (figure 3-1, 3-2b). Similar results were observed 
when MCF-7 cells were treated with 0.5uM PST in combination with 5uM Tamoxifen. A 
concentration of 0.5 uM PST on its own induced approximately 45% apoptosis after of 72 
hours treatment; however, in combination with 5uM Tamoxifen (the concentration were 
no effect was observed), the apoptotic index increased to 65% apoptosis, which 
corresponds to an apoptotic increase of 20% (figure 3-1,3-2a, 3-2c). 
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Figure 3-1: Apoptotic Index: Dose response of MCF-7 cells to Pancratistatin and Tamoxifen. MCF-
7 cells were treated with PST and Tamoxifen for 72 hours and stained with Hoechst 333423 dye. The 
number of apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from 
a minimum of 500 cells. Standard error was calculated using data from a minimum of three separate 
experiments. 
Figure 3-2a: Synergistic response of MCF-7 cells to Pancratistatin and Tamoxifen 
Treatment MCF-7 
Control 5|JM Tmoxifen 10|JM Tamoxifen 
0:5pM PST 1yM PST 0.5|JM PST + 5|JM Tarn 
Figure 3-2a: Synergistic response of MCF-7 cells to Pancratistatin and Tamoxifen treatment MCF-7. 
MCF-7 cells were treated with PST and tamoxifen for 72 hours and stained with Hoechst 33342 dye to 
examine nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear 
condensation is evident in cells with bright, condensed, and rounded nuclei. 
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Figure 3-2b: Apoptotic Index: Synergy of PST and Tamoxifen at High Dose PST 
Control 1 |JMPST + 1 tJMPST + 1MMPST + 
1HMTAM 5MMTAM 10|jMTAM 
Treatment 
Figure 3-2b: Apoptotic Index: Synergy of PST and Tamoxifen at high dose PST. MCF-7 cells were 
treated in combination with 1 uM PST and various concentrations of Tamoxifen for 72 hours and stained 
with Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of 
apoptotic cells was calculated from a minimum of 500 cells. Standard error was calculated using data from 
a minimum of three separate sets of experiments. 
Figure 3-2c: Apoptotic Index: Synergy of PST and Tamoxifen at Low Dose PST 
100 
! 
Control 0.5|jMPST+ 0 .5UMPST + 0.5|JMPST + 
1MMTAM 5UMTAM IOMMTAM 
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Figure 3-2c: Apoptotic Index: Synergy of PST and Tamoxifen at low dose PST. MCF-7 cells were 
treated in combination with 0.5 uM PST and various concentrations of Tamoxifen for 72 hours and stained 
with Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of 
apoptotic cells was calculated from a minimum of 500 cells. Standard error was calculated using data from 
a minimum of three separate sets of experiments. 
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3.1.3 Induction of Apoptosis in ER- Hs578-T Cells by PST Treatment 
Estrogen receptor negative Hs578-T cells were treated with 0.5uM and luM PST 
treatment for 72 hours and quantified by Hoechst-33342 dye in order to examine nuclear 
condensation and develop apoptotic indexes to establish the relative apoptotic effect as 
compared to a control. Apoptotic nuclear morphology was observed upon the addition of 
0.5uM and luM PST in the form of condensed bright nuclei (figure 3-3a). As observed 
in figure 3-3b, 0.5 uM PST treatment caused 20% apoptosis while 1 uM PST treatment 
exhibited approximately 45% apoptosis for 72 hours. 
3.1.4 Synergistic Action of PST and Tamoxifen in ER- Hs578-T Cells 
Tamoxifen, an estrogen receptor antagonist, has been recently observed to induce 
apoptosis by directly destabilizing cancer cell mitochondria through the 
flavomononucleotide (FMN) binding site on complex 1 of the electron transport chain 
(Moreira et. al. 2006). Here, the effect of Tamoxifen was considered in estrogen receptor 
negative cells in combination with PST in order to observe a potential to exploit the 
Tamoxifen targeted mitochondrial membrane dysfunction. To examine whether a 
synergistic relationship exists between these agents, various concentrations of PST and 
Tamoxifen were combined and incubated with Hs578-T cells for 72 hours and 
quantitatively analyzed by Hoechst 33342 staining as per protocol. Figure 3-3a shows 
that the addition of lOuM Tamoxifen over 72 hours exhibited little apoptotic nuclear 
morphology when compared to control; however, the addition of 0.5uM PST in 
combination with lOuM Tamoxifen increased the apoptotic response of the 0.5uM PST 
treatment. 
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Furthermore, apoptotic indices were established from counting the number of 
cells which demonstrate condensed apoptotic nuclei. As observed in figure 3-3b Hs578-T 
cells treated with 10uM Tamoxifen for 72 hours exhibited minimal apoptotic 
morphology. The combined treatment of 0.5 uM PST and lOuM Tamoxifen for 72 hours 
exhibited approximately 40% apoptosis which corresponds to a 20% increase from 
0.5uM PST on its own (figure 3-3b). 
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Figure 3-3a: Synergistic Response of Hs578-T Cells to PST and Tamoxifen 
Treatment for 72 Hours 
Control 0 5|JM PST 0 ,5|JM PST + 1 0|JM Tamoxife n 
1yMPST 10pM Tamoxifen 1 pM PST + 10pM Tamoxifen 
Figure 3-3a: Synergistic response of Hs578-T cells to Pancratistatin and Tamoxifen treatment. 
Hs578-T cells were treated with various concentrations of PST and Tamoxifen for 72 hours and stained 
with Hoechst 33342 dye to examine nuclear morphology. Fluorescent pictures were taken at 40x 
magnification. Nuclear condensation is evident in cells with bright, condensed, and rounded nuclei. 
Figure 3-3b: Apoptotic Index: Synergistic response of Hs578-T cells to PST and 
Tamoxifen Treatment 
1 (JM PST +10|jM Tarn 
1pM PST+ 5pM Tarn 
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Figure 3-3b: Apoptotic Index: Synergistic response of Hs578-T cells to Pancratistatin and 
Tamoxifen treatment. Hs578-T cells were treated in combination with various PST and Tamoxifen 
concentrations for 72 hours and stained with Hoechst 33342 dye. The number of apoptotic nuclei was 
counted and the average percentage of apoptotic cells was calculated from a minimum of 500 cells. 
Standard error was calculated using data from a minimum of three separate sets of experiments. 
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3.1.5 NHF Cells Un-effected by Combined PST and Tamoxifen Treatment 
Minimal toxicity to normal cells is an important characteristic in noval 
chemotherapeutic strategies to avoid the harsh side effects that arise from current cancer 
therapies. Toxicity to normal cells due to current chemotherapies such as taxol and 
topoisomerase II inhibitors has been attributed with re-occurrence of disease and 
establishment of secondary tumors (Cunha et. al. 2001, Boos, Stopper 2000). Therefore 
compounds which reduce the risk of side-effects are the focus of modern research. As 
previously mentioned PST has been shown to exhibit no toxic effect to normal tissue 
(Pandey et. al. 2001, McLachlan et. al. 2005). Furthermore, Tamoxifen has been reported 
to exhibit minimal toxicity to normal tissue (Duffy 2005). Therefore the combinatorial 
treatment of both compounds was considered in a normal non-cancerous cell line to 
examine the potential for toxicity. 
To determine the effect of combined PST and Tamoxifen treatment on normal cell 
lines we chose to treat normal human fibroblasts (NHF). There was no evidence 
suggesting toxicity of combination treatment to these cells after 72 hours. Figure 3-4a 
and 3-4b shows that combinatorial treatments of lOuM Tamoxifen and luM PST did not 
induce significant nuclear condensation when compared to untreated NHF cells. 
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Figure 3-4a: Combinatorial Treatment of PST and Tamoxifen in NHF Cells 
Control 1QMM Tamoxifen 
1|JMPST 1pMPST+10jjMTam 
Figure 3-4a: Combinatorial Treatment of PST and Tamoxifen in NHF. Cells NHF cells were treated 
with various concentrations of PST and tamoxifen for 72 hours and stained with Hoechst 33342 dye to 
examine nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear 
condensation is evident in cells with bright, condensed, and rounded nuclei. 
Figure 3-4b: Apoptotic Index: Combinatorial Treatment of NHF Cells to PST and 
Tamoxifen for 72 Hour 
1^M PST+ lO^MTam 
1pM PST+ 5pMTam 
0.5|jM PST+ 10pM Tam 
C 0.5|jM PST + 5pM Tam 
J5 10uM Tamoxifen 
£ 5|jM Tamoxifen 
1 MM PST 
0.5|JM PST 
Control 
0 10 20 30 40 50 60 70 80 90 100 
% Apoptosis 
Figure 3-4b: Apoptotic Index: Combinatorial Treatment of NHF Cells to PST and Tamoxifen for 72 
Hour, treated for 72 hours and stained with Hoechst 33342 dye. The number of apoptotic nuclei was 
counted and the average percentage of apoptotic cells was calculated from a minimum of 500 cells. 
Standard error was calculated using data from a minimum of three separate sets of experiments. 
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3.1.6 Quantitative Analysis of Apoptotic Synergy in MCF-7 Cells 
The synergistic effect in MCF-7 cells was quantitatively analyzed by flow 
cytometry utilizing Annexin-V FITC conjugate binding. MCF-7 cells were treated with 
0.5uM PST and/or 5uM Tamoxifen for a period of 72 hours and incubated with Annexin-
V FITC conjugate. Percent positive staining was obtained from a population of 20 000 
cells. Figure 3-5a shows that treatment with 5uM Tamoxifen resulted in 14.27% positive 
Annexin-V staining, which is not a significant increase over control cells which stained 
13.88% Annexin-V positive. Furthermore figure 3-5a shows that treatment with 0.5uM 
PST resulted in 34.45% positive Annexin-V staining in MCF-7 cells and the combined 
treatment of 0.5uM PST and 5uM Tamoxifen resulted in 52.63% Annexin-V positive 
staining which corresponds to a 20% increase from the single treatment with PST. 
The level of DNA fragmentation was investigated by TUNEL assay and 
quantified by flow cytometry. MCF-7 cells were treated with 0.5 uM PST and/or 5uM 
Tamoxifen for 72 hours upon which the TUNEL assay was performed as per 
manufacturer's protocol. Cells were properly gated and 20 000 cells were analyzed. 
Figure 3-5b shows that 11.85% of untreated MCF-7 cells were positively stained for 
DNA fragmentation and 5uM Tamoxifen treatment resulted in 15.78% positive staining. 
Furthermore, figure 3-5b demonstrates that MCF-7 cells treated with 0.5 uM PST resulted 
in 44.29% positive staining, while the combination of 0.5uM PST and 5uM Tamoxifen 
resulted in 48.88% of cells to stain positively. 
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Figure 3-5a: Flow Cytometry: Annexin-V Analysis of PST and Tamoxifen Synergy 
in MCF-7 Cells 
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Figure 3-5a: Flow Cytometry: Annexin-V analysis of PST and Tamoxifen synergy in MCF-7 cells. 
MCF-7 cells were treated with 0.5uM PST, 5nM Tamoxifen and a combination of both for 72 hours. Total 
cell counts of 20,000 were gated and analyzed by flow cytometry operator. Annexin V-FITC positive cells 
were then taken as % Gated. 
Figure 3-5b: Flow Cytometry: TUNEL Analysis of PST and Tamoxifen Synergy in 
MCF-7 Cells 
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Figure 3-5b: Flow Cytometry: TUNEL analysis of PST and Tamoxifen synergy in MCF-7 cells. MCF-
7 cells were treated with 0.5 uM PST, 5uM Tamoxifen and a combination of both for 72 hours. Total cell 
counts of 20,000 were gated and analyzed by flow cytometry operator. TUNEL positive cells were then 
taken as % Gated. 
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3.1.7 Whole Cell ROS Increases upon Combinatorial PST and Tamoxifen 
Treatment 
Increase in whole cell ROS is attributed to the dysfunction of the mitochondrial 
membrane and eminent apoptosis (Somayajulu et. al. 2005). Whole cell ROS was 
measured by the fluorometric assay using H2DCFDA fluorophore. Cancerous and non-
cancerous cell lines were treated with PST and Tamoxifen upon which relative whole cell 
ROS was measured. 
MCF-7 (ER+) and Hs578-T (ER-) were grown on 24-well culture plates and 
treated with 0.5uM PST, 5uM Tamoxifen or a combination of both for a period of 24 
hours, upon which whole cell ROS was measured as per protocol. As observed in figure 
3-6a, the combined treatment of 0.5uM PST and 5uM Tamoxifen increased the relative 
amount of ROS production in MCF-7 cells more so then either drug on its own. Similar 
results were obtained in the ER- Hs578-T cell line (figure 3-6b) as combined treatment of 
0.5uM PST and 5uM increased the relative amount of ROS in greater amount then either 
drug alone. Furthermore to test the effect of combined PST and Tamoxifen in normal 
human fibroblast (NHF) cells we treated them with higher doses of PST and Tamoxifen 
to determine if there are any changes in the total ROS production. As was observed in 
figure 3-6c, there was no significant increase from control upon the addition of luM 
PST, lOuM Tamoxifen and a combination of both, at these concentrations. 
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Figure 3-6a: Whole Cell ROS of MCF-7 cells treated with PST and Tamoxifen. MCF-7 cells were 
incubated with 0.5 [iM PST, 5uM Tamoxifen and a combination of both for a period of 24 hours then 
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were 
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 separate 
trials of the experiment. 
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Figure 3-6b: Whole Cell ROS of Hs578-T cells treated with PST and Tamoxifen. Hs578-T cells were 
incubated with 0.5 uM PST, 5[xM Tamoxifen and a combination of both for a period of 24 hours then 
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were 
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 trials of the 
experiment. 
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Figure 3-6c: Whole Cell ROS of NHF cells treated with PST and Tamoxifen. NHF cells were 
incubated with l^iM PST, lO^M Tamoxifen and a combination of both for a period of 24 hours then 
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were 
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 trials of the 
experiment. 
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3.1.8 Mitochondrial membrane potential collapse upon treatment of PST and 
Tamoxifen 
As previously mentioned, increase in ROS generation is indicative of 
mitochondrial dysfunction within the cell. In order to determine if mitochondria are 
destabilized following treatment we used a mitochondria permeable assay. This assay 
uses a cationic JC-1 dye, which localizes to mitochondria with adequate mitochondrial 
membrane potential and is retained within this membrane were it gives off a red 
fluorescent stain, when not localized to mitochondria JC-1 dye will fluoresce green in the 
cytosol. Both ER+ and ER- breast cancer cell lines were treated at the previously 
determined doses of PST (0.5uM) and Tamoxifen (5uM) which exhibit greatest 
synergistic behavior, for 48 hours. Normal human fibroblasts were treated as a control to 
compare the effect of the treatment. 
In figure 3-7a clear red punctuate staining is observed in both the control and 48h 
Tamoxifen treated MCF-7 cells. It is evident from figure 3-7a that the red mitochondrial 
staining becomes relatively more diffuse in 0.5 uM PST treated cells. Red punctuate 
mitochondrial staining is even more diffuse in the combinatorial treatment of 0.5uM PST 
and 5uM Tamoxifen as is evident by the increase in green background staining (figure 3-
7a). 
As can be seen from figure 3-7b, in Hs578-T cells, control and lOuM Tamoxifen 
exhibited approximately the same red punctuate staining; however, the JC-1 stain of the 
combined treatment of 0.5uM PST and lOuM Tamoxifen indicate greater diffuse red 
staining then either of the compounds separately. Furthermore normal human fibroblast 
cells did not exhibit substantial changes in the amount of red punctuate JC-1 staining as 
shown in figure 3-7c, when treated with 0.5uM PST and 5uM Tamoxifen. 
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Figure 3-7a: Mitochondrial Membrane Permeability in MCF-7 Cells Treated by 
PST and Tamoxifen: JC-1 Staining 
Control ^[iM Tamoxifen 
0.5|JM PST 0.5|JM PST 5|JM Tarn 
Figure 3-7a: Mitochondrial membrane permeability in MCF-7 cells treated by PST and Tamoxifen: 
JC-1 staining. MCF-7 cells were treated with 0.5 jiM PST and 5(iM Tamoxifen for a period of 48 hours at 
which point JC-1 dye was applied to the cells to examine mitochondrial membrane potential. Fluorescent 
pictures were taken at 400x magnification. Bright red florescence is indicative of healthy mitochondria 
with intact membrane potential. 
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Figure 3-7b: Mitochondrial Membrane Permeability in Hs578-T Cells Treated by 
PST and Tamoxifen: JC-1 Staining 
Control 0 .5|JM PST 
1 0|JM Tamoxifen 0 .5|JM PST + 10|JM Tam 
Figure 3-7b: Mitochondrial membrane permeability in Hs578-T cells treated by PST and 
Tamoxifen: JC-1 staining. Hs578-T cells were treated with 0.5u.M PST and lOfiM Tamoxifen for a 
period of 48 hours at which point JC-1 dye was applied to the cells to examine mitochondrial membrane 
potential. Fluorescent pictures were taken at 400x magnification. Bright red florescence is indicative of 
healthy mitochondria with intact membrane potential. 
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Figure 3-7c: Mitochondrial Membrane Permeability in NHF Cells Treated by PST 
and Tamoxifen: JC-1 Staining 
Control 0.5|JM PST 
5|JM Tamoxifen 0.5|JM PST + 5|JM Tarn 
Figure 3-7c: Mitochondrial membrane permeability in NHF cells treated by PST and Tamoxifen: 
JC-1 staining. NHF cells were treated with 0.5^M PST and 5fiM Tamoxifen for a period of 48 hours at 
which point JC-1 dye was applied to the cells to examine mitochondrial membrane potential. Fluorescent 
pictures were taken at 400x magnification. Bright red florescence is indicative of healthy mitochondria 
with intact membrane potential. 
60 
3.1.9 Mitochondria as the Target for PST and Tamoxifen Induced Apoptosis 
PST has previously been shown to exhibit its activity directly on the mitochondria 
of cancerous cells and Tamoxifen has been observed to have mitochondrial targets 
independent of estrogen receptor activity. Therefore, to test the effect of both compounds 
on the mitochondria directly, we isolated mitochondria from MCF-7, Hs578-T and NHF 
cell lines and treated their isolated mitochondria directly with PST, Tamoxifen and a 
combination of both for a total of 1.5 hours. Paraquat which increases mitochondrial 
ROS was used as a positive control. Upon treatment of mitochondria with the compounds 
a fluorometric assay was utilized. This assay works by coupling a reaction involving: 
reduction of Amplex Red dye reagent with oxidation of hydrogen peroxide through the 
action of horse radish peroxidase enzyme. 
Figure 3-8a shows that the treatment of MCF-7 mitochondria with 5uM 
Tamoxifen did not generate significant mitochondrial ROS increases when compared to 
control and MCF-7 mitochondria treated with 0.5 uM PST increases the relative amount 
of mitochondrial ROS. Figure 3-8a demonstrates that 5uM Tamoxifen and 0.5uM PST 
significantly increase the relative amount of mitochondrial ROS, more so then either 
compound separately. 
To test the mitochondrial response in estrogen receptor negative cells, we isolated 
mitochondria from Hs578-T cells and incubated them with the various treatments. As can 
be seen in figure 3-8b the mitochondrial ROS response in Hs578-T cells is similar to that 
observed in the estrogen receptor positive MCF-7 mitochondria, where the addition of the 
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double treatment 5uM Tamoxifen and 0.5u PST increased the relative ROS in greater 
amount then either compound separately. 
To investigate the response of normal "healthy" mitochondria, we isolated 
mitochondrial fractions from normal human fibroblast cells and treated them in the same 
manner as the ER- and ER+ cell lines. As clearly shown in figure 3-8c, there was no 
significant ROS increase from control when isolated mitochondria from NHF cells were 
treated with 0.5uM PST, 5uM Tamoxifen and both. To observe increased mitochondrial 
ROS response from the mitochondrial preparations, we treated them with lOOuM 
Paraquat, which was observed to increase the ROS significantly (figure 3-8c). 
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Figure 3-8a: Mitochondrial ROS measurement isolated from MCF-7 cells. Isolated MCF-7 cell 
mitochondria were incubated directly with 0.5 uM PST, 5\iM Tamoxifen and a combination of both. The 
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings 
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion 
of 3 separate experiments. 
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Figure 3-8b: Mitochondrial ROS measurement isolated from Hs578-T cells. Isolated Hs578-T cell 
mitochondria were incubated directly with 0.5 ̂ M PST, 5[xM Tamoxifen and a combination of both. The 
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings 
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion 
of 3 separate experiments. 
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Figure 3-8c: Mitochondrial ROS Measurement Isolated From NHF Cells 
600 T 
0 \ -. 1 r- r-- , , 1 
0 10 20 30 40 50 60 70 
Time (min) 
Figure 3-8c: Mitochondrial ROS measurement isolated from NHF cells. Isolated NHF cell 
mitochondria were incubated directly with 0.5 uM PST, 5uM Tamoxifen and a combination of both. The 
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings 
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion 
of 3 separate experiments. 
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3.1.10 PST and Tamoxifen Cause Release of Cytochrome c Synergistically in 
Isolated MCF-7 Mitochondria 
To investigate Cytochrome c release from isolated mitochondria after PST 
treatment, we prepared isolated mitochondrial fractions from MCF-7 cells. Polyclonal 
anti-Cytochrome c antibody was used to probe for Cytochrome c retained within the 
mitochondria after the 2 hour incubation period. Anti-Succinate dehydrogenase antibody 
was used as a mitochondrial loading control. The concentrations used to treat isolated 
mitochondrial fractions include: 0.5uM, luM, 2uM, 4uM and 8uM PST and figure 
shows 3-9a that 0.5uM PST did not significantly reduce the amount of Cytochrome c 
retained within the mitochondria. Figure 3-9a shows that concentrations of 1 uM PST and 
greater were required to significantly reduce the amount of Cytochrome c retained in the 
mitochondrial pellets. 
To study the relative effect of combined PST and Tamoxifen treatment on isolated 
mitochondria preparations, we incubated mitochondrial pellets prepared from MCF-cells, 
for a period of 2 hours, with 0.5uM PST and 5uM Tamoxifen. It was observed from 
figure 3-9b that 0.5uM PST did not reduce the amount of Cytochrome c retained within 
the mitochondria when compared with the control. As shown in figure 3-9b 5uM 
Tamoxifen did not significantly reduce the amount of Cytochrome c retained in the 
mitochondrial pellets, however the combined treatment of 0.5 uM PST and 5uM 
Tamoxifen was sufficient to decrease the amount of Cytochrome c retained within the 
mitochondria. 
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Figure 3-9a: Retention of Cytochrome c Upon Treatment of PST Directly on 
Isolated MCF-7 Mitochondria. 
MW Control O.SpM \\M 2\M i,\M 8|jM 
Anti-Cyt C -» 
Anti-SDH-> 
Figure 3-9a: Retention of Cytochrome c upon treatment of PST directly on MCF-7 isolated 
mitochondria. Approximately 100|xg of mitochondrial protein was incubated with indicated concentrations 
of PST for a period of 2 hours upon which time mitochondrial pellets were loaded onto a polyacrylamid gel 
and blotted for cytochrome C and succinate dehydrogenase. 
Figure 3-9b: Retention of Cytochrome c Upon the Combinatorial Treatment of PST 
and Tamoxifen Directly on Isolated MCF-7 Mitochondria. 
Control 0.5^JM PST 5uM Tam 0.5tiM PST + 5[JM Tarn 
Anti-Cyt C -> 
Anti-SDH -> 
Figure 3-9b: Retention of Cytochrome C upon the combinatorial treatment of PST and Tamoxifen 
directly on MCF-7 isolated mitochondria. Approximately 100[xg of mitochondrial protein was incubated 
with 0.5^M PST and 5\iM Tamoxfen for a period of 2 hours upon which time mitochondrial pellets were 
loaded onto a polyacrylamid gel and blotted for cytochrome C and succinate dehydrogenase. 
67 
3.2 Insights into the Mechanism of PST Induced Apoptosis 
Apoptosis induction caused by PST has been well established in our lab, however 
specific questions with respect to the internal biochemical response remain. We looked at 
levels of pro/anti-apoptotic proteins and caspase-8 activation in MCF-7, Hs578-T and 
NHF cells. Furthermore we examined MCF-7 cells for resistance over prolonged sub-
lethal PST incubation. 
3.2.1 Pro/Anti-apoptotic Protein Expression and Localization Upon PST Treatment 
in Hs578-T, MCF-7 and NHF Cells 
To gain insights into biochemical mechanism of PST we probed cytosolic and 
mitochondrial fractions of MCF-7, Hs578-T and NHF cells with specific bcl-2 pro and 
anti-apoptotic protein antibodies to check for cellular expression and localization. Cells 
were treated with 1 uM PST for 48 hours, homogenized and fractionated as per protocol, 
40ug of proteins from the separate fractions were analyzed by western blot for the 
indicated antibody as per protocol. The polyclonal antibodies used for the western blot 
analysis include: anti-Bax, anti-Bad, anti-Bcl-2, anti-Bcl-xl, anti-Cytochrome C and anti-
Succinate dehydrogenase. 
We investigated the response of MCF-7 cells to 1 uM PST treatment with respect 
to localization and expression of pro/anti-apoptotic proteins in cytosolic and 
mitochondrial fractions. Figure 3-10a shows that the cytosolic fraction of MCF-7 cells 
treated with 1 uM PST for 48 hours exhibited significantly higher amounts of Bad pro-
apoptotic protein and significantly lower amounts of Bax pro-apoptotic protein as 
compared to the control un-treated cells. The mitochondrial fraction was probed for 
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Cytochrome c and Bax and it was observed in figure 3-10b that the levels of cytochrome 
c decreased and the levels of Bax increased in the treated cells. 
The breast cancer cell line Hs578-T was also analyzed for the expression anti/pro-
apoptotic proteins under the same conditions as the MCF-7 cells to co-relate the overall 
response to treatment with luM PST for 48 hours. As observed in figure 3-10b the 
cytosolic fraction levels of Bcl-2 are decreased and the levels of both Bax and Bad 
increased. In addition figure 3-10b shows that in mitochondrial fractions the levels of 
Cytochrome c is decreased and levels of Bax are increase in the treated Hs578-T cells. 
Analysis of pro/anti-apoptotic proteins in normal human fibroblast cells (NHF) 
revealed no significant changes in protein expression and localization as can be seen in 
figure 3-lla and 3-llb. 
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Figure 3-10a: Cytosolic fraction of MCF-7 cells treated with luM PST. MCF-7 cells were treated for a 
period of 48 hours. Cells were harvested and cytosolic fractions were isolated as per protocol. Western 
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the 
relative treated to control ratio (right column). 
Figure 3-10b: Mitochondrial Fraction of MCF-7 Cells Treated with luM PST 
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Figure 3-10b: Mitochondrial fraction of MCF-7 cells treated with luM PST. MCF-7 cells were treated 
for a period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per protocol. 
Western blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to 
analyze the relative treated to control ratio (right column). 
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Figure 3-lla: Cytosolic fraction of Hs578-T cells treated with luM PST. Hs578-T cells were treated for 
a period of 48 hours. Cells were harvested and cytosolic fractions were isolated as per protocol. Western 
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the 
relative treated to control ratio (right column). 

















Figure 3-llb: Mitochondrial fraction of Hs578-T cells treated with luM PST. Hs578-T cells were 
treated for a period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per 
protocol. Western blots were then run as per protocol and blotted for specified antibodies. ImageJ was used 
to analyze the relative treated to control ratio (right column). 
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Figure 3-12a: Cytosolic fraction of NHF cells treated with luM PST. NHF cells were treated for a 
period of 48 hours. Cells were harvested and cytosolc fractions were isolated as per protocol. Western blots 
were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the relative 
treated to control ratio (right column). 














Figure 3-12b: Mitochondrial fraction of NHF cells treated with luM PST. NHF cells were treated for a 
period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per protocol. Western 
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the 
relative treated to control ratio (right column). 
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3.2.2 Hs-578-T and MCF-7 Cells Exhibit Late Caspase-8 Activation 
The analysis of live cell caspase-8 activation was investigated in MCF-7, Hs578-
T and NHF cells. The incubation of 1 uM PST for the indicated time points revealed late 
caspase-8 activation in both cancer cell lines (MCF-7 and Hs578-T). Figure 3-13a shows 
that MCF-7 cells exhibit late (24 hour) caspase-8 activation. As can be observed in figure 
3-13b the Hs578-T cells exhibit significant caspase-8 activation at 48 hours. 
Furthermore, as shown in figure 3-13c, no caspase-8 activation was observed in luM 
PST treated NHF cells. 
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Figure 3-13a: MCF-7 Caspase-8 Live Assay 
Control 6 hour 24 hour 48 hour 
Time 
Figure 3-13a: MCF-7 caspase-8 live assay. MCF-7 cells were incubated with luM PST for the indicated 
times at which point a cell permeable FAM-LETD-FMK substrate was added to detect the relative 
fluorescence using a flouriometer set at excitation 488nm and emission 520nm. After the assay cells were 
counted and the relative fluorescent units per 10,000 cells was expressed. 
Figure 3-13b: Hs578-T Caspase-8 Live Assay 
50 -i 
© 40 f 
Control 6 hour 24 hour 48 hour 
Time 
Figure 3-13b: Hs578-T caspase-8 live assay. Hs578-T cells were incubated with luM PST for the 
indicated times at which point a cell permeable FAM-LETD-FMK substrate was added to detect the 
relative fluorescence using a flouriometer set at excitation 488nm and emission 520nm. After the assay 
cells were counted and the relative fluorescent units per 10,000 cells was expressed. 
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Figure 3-13c: NHF caspase-8 live assay. NHF cells were incubated with 1 uM PST for the indicated times 
at which point a cell permeable FAM-LETD-FMK substrate was added to detect the relative fluorescence 
using a flouriometer set at excitation 488nm and emission 520nm. After the assay cells were counted and 
the relative fluorescent units per 10,000 cells was expressed. 
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3.2.3 MCF-7 Cells Do Not Exhibit Resistance to PST 
While the overall response rate to treatment can be high in breast cancer cells, the 
duration of response is relatively short, and it has been observed that initially responsive 
breast tumors acquire a multidrug resistance phenotype (Trock et. al. 1997). This 
phenotype is frequently characterized by a cross-resistance to drugs to which the tumors 
have not been exposed. The development of a multidrug resistant phenotype in metastatic 
breast cancer is primarily responsible for the failure of current treatment regimens (Trock 
et. al. 1997). 
To test the potential of resistance to PST by MCF-7 cells we pre-incubated these 
cells with sub-lethal doses of PST and after a period of time we challenged these cells 
with the lethal luM dose. MCF-7 cells were treated with 25nM and 50nM PST for 20 
days upon which the cells were challenged with luM PST for 72 hours. After the 72 hour 
incubation period MCF-7 cells were treated with the lethal dose of luM PST. Cells were 
then incubated with Hoechst 33342 dye and stained nuclei counted. Figure 3-14 shows 
that there was no difference in the degree of apoptosis induction between MCF-7 cells 
pre-treated with sub-lethal doses of PST and MCF-7 control (not pre-treated), as both 
types of cells exhibited the same apoptotic response upon 72 hour incubation with 1 uM 
PST. 
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Figure 3-14: Apoptotic Index of Resistance to PST Treatment 
Control lMMPSTfor72hr 25nM PST Treated for 20 
days + 1|jM PST for 72hr 
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50nM Treated for 20 days + 
1|jMPSTfor72rir 
Figure 3-14: Apoptotic Index of Resistance to PST Treatment. MCF-7 cells were pre-treated for 20 
days with sub-lethal 25 and 50nM PST treatments. After 20 days cells were re-plated and treated with 
lethal dose ofluM PST for 72 hours. Hoechst 33342 dye was added and the number of cells exhibiting 
apoptotic nuclear morphology was counted. 
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3.3 Preliminary Study of in-vivo PST and Tamoxifen Induced Apoptosis 
To test the effect of PST and Tamoxifen in-vivo, a RAG 2M mouse model was 
developed. Ten immunocompromised RAG 2M mice with disrupted recombination 
activating gene-2 were used in the model. Time release 17p-estradiol pellets were 
injected sub-cutaneously into the neck of each mouse using a trochar device to achieve 
maximum tumor growth (Webb et. al. 2007). Tumors were generated by injecting 6 x 
10A6 MCF-7 cells subcutaneously into hind flank each mouse. Tumors were allowed to 
grow for approximately 2 weeks after initial injection until an approximate size of 5mm 
in diameter was visible. Mice were then selected and grouped according to relative tumor 
size for treatments. Four groups were generated with placebo (peanut oil), PST (3mg/kg), 
Tamoxifen (25mg/kg), and both PST (3mg/kg) and Tamoxifen (25mg/kg). Intra tumoral 
PST injections were given twice a week and intra peritoneal Tamoxifen injections were 
given 3 times up to a total of 10 PST injections and 14 Tamoxifen injections over 5 
weeks on the 6th week the mice were put down. Over the course of the experiment 2 mice 
died in their cage unexpectedly (PST and Tamoxifen) and therefore the data presented is 
based on results from the remaining mice. 
3.3.1 Breast Cancer Tumors Successfully Generated In RAG 2M Mice 
We attained a 100% success rate in the development of human breast cancer 
tumors in each of the mice injected in the study. Figure 3-15 shows clearly visible 
subcutaneous tumors. Due to the hair on the mice it was difficult to measure the 
progression of tumor size over the course of treatment and so therefore only gross weight 
measurements were recorded during the treatment phase of the experiment. A total of six 
78 
weight measurements were taken over the course of the study as observed in figure 3-16 
there were no significant changes in the gross weights of the mice. This data is 
preliminary and needs to be repeated to generate accurate results. 
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Figure 3-15: Tumorigenesis in RAG 2M Mouse Model 
Figure 3-15: Tumorigenesis in RAG 2M mouse model established by the injection of 6 x 10 MCF-7 






Figure 3-16: Gross weight Measurements of Mice 
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Figure 3-16: Gross weight measurements of mice. RAG 2M Mice were weighed 6 times over a 5 week 
period as part of handling procedure to record the total weight of the mouse over the course of treatment. 
Plotted is the weight of mice in the experimental groups which include: Placebo, PST, Tamoxifen (TAM) 
and PST + TAM. 
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3.3.2 TUNEL and DAPI Staining Reveal No Toxicity To Kidney and Liver 
To evaluate genotoxicity of the treatments to organ tissue, the kidney and liver of 
each mouse was removed and prepared in wax blocks at which point 8 micron sections 
were prepared on slides as per protocol. Terminal Uridine Nick End Labeling assay was 
carried out as mentioned in materials and methods in order to evaluate the integrity of 
DNA. Each slide was also stained with DAPI to evaluate the nuclear morphology of the 
cells. All results are preliminary and will require further testing to validate. 
The liver of each mouse was analyzed and figure 3-17a shows that there was no 
positive TUNEL staining for any of the treatment groups. The DAPI stains revealed that 
the nuclear morphology of the tissues appeared consistently healthy across all test groups 
(figure 3-17a). 
The kidneys of each mouse were also removed and sectioned as per protocol to 
check for potential genotoxicity. Figure 3-17b shows that no apparent genotoxic effects 
were observed when analyzing the TUNEL stains qualitatively. The lack of TUNEL 
staining in these tissues (figure 3-17b) directly indicates the lack of nicks in the nuclear 
DNA which co-relates to the lack of genotoxicity in all samples analyzed. From 
qualitative analysis of the DAPI stains in 3-17b it was revealed that the nuclear 
morphology does not change between the 3 treatments (PST, Tamoxifen, and PST + 
Tamoxifen) when compared to the placebo. 
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3.3.3 TUNEL and DAPI Staining Reveal Toxicity to Treated Tumor Samples 
From our preliminary data it was observed that tumor samples from the treated 
groups (PST, Tamoxifen and PST + Tamoxifen) exhibited positive TUNEL labeling 
when compared to placebo. As observed in figure 3-17c there appears to be TUNEL 
DNA labeling particularly in the PST + Tamoxifen treated tumors (as denoted by bright 
green fluorescence). There also seems to be a greater intensity of DAPI staining in the 
PST + Tamoxfen treated tumors (figure 3-17c). TUNEL labeling was also observed to a 
lesser extent in PST or Tamoxifen alone; however these observations are only 
preliminary and more testing will be required to validate the findings. 
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Figure 3-17a: TUNEL Labeling and DAPI Staining of Liver Tissue Samples 
Placebo PST Tamoxifen PST + TAM 
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Figure 3-17a: TUNEL labeling and DAPI staining of liver tissue samples. Liver sections for each 
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright 
TUNEL staining indicated DNA nicks. 
Figure 3-17b: TUNEL Labeling and DAPI Staining of Kidney Tissue Samples 
Placebo PST Tamoxifen PST + TAM 
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Figure 3-17b: TUNEL labeling and DAPI staining of kidney tissue samples. Kidney sections for each 
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright 
TUNEL staining indicated DNA nicks. 
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Figure 3-17c: TUNEL Labeling and DAPI Staining of Tumor Tissue Samples 
Placebo PST Tamoxifen PST + TAM 
Figure 3-17c: TUNEL labeling and DAPI staining of Tumor tissue samples. Tumor sections for each 
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright 
TUNEL staining indicated DNA nicks. 
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3.3.4 Histological Analysis of Tissues Using Hemotoxalyn and Eosin 
To analyze the overall morphology of the tissue samples, we analyzed the 
sectioned liver, kidney and tumor samples using hematoxylin and eosin staining. 
Hematoxalyin stains the nucleus and eosin stains the cytoplasm thus visualization of the 
morphological features of a cell becomes possible. Proper histochemical analysis will 
have to be performed by a trained pathologist these observations are only qualitative and 
preliminary. 
Figure 3-18a shows that the liver samples in all treatments appear to be relatively 
same in consistency with respect to nuclear and cellular morphology. As observed in 
figure 3-18a there does not appear to be any morphological changes when compared to 
placebo. Furthermore, analysis of the kidney samples exhibited similar staining in all the 
treatment samples studied (figure 3-18b). Therefore no severe liver and kidney cellular 
changes were observed when comparing the treatment groups to placebo indicating 
minimal effect towards treatment. 
Tumor samples analyzed by hematoxalyn and eosin revealed interesting 
morphological features in the different treatment groups. It was found that the density of 
cells appeared to be higher in placebo and Tamoxifen groups (figure 3-18c). It is 
observed that the morphology of the treatment groups, in particular the combined 
treatment of PST + Tamoxifen, had drastic effects on the morphology of the cells (figure 
3-18c). Tamoxifen + PST treated tumors exhibtit inconsistencies in nuclear shape and 
cellular density (figure 3-18c). These insights are preliminary observations and the slides 
must be properly analyzed by a trained pathologist. 
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Figure 3-18a: Hematoxylin and Eosin Stain: Liver Morphology 
Placebo PST 
Tamoxifen PST + Tamoxifen 
Figure 3-18a: Hematoxylin and eosin stain: liver morpholgy. Tissue morphology was analyzed by 
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x 
magnification using a phase-contrast light microscope and observed by motic imaging software. 
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Figure 3-18b: Hematoxylin and Eosin Stain: Kidney Morphology 
Placebo PST 
Tamoxifen PST + Tamoxifen 
Figure 3-18b: Hematoxylin and eosin stain: kidney morpholgy. Tissue morphology was analyzed by 
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x 
magnification using a phase-contrast light microscope and observed by motic imaging software. 
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Figure 3-18c: Hematoxylin and Eosin Stain: Tumor Morphology 
Placebo PST 
Tamoxifen PST + Tamoxifen 
Figure 3-18c: Hematoxylin and eosin stain: tumor morphology. Tissue morphology was analyzed by 
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x 
magnification using a phase-contrast light microscope and observed by motic imaging software. 
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3.3.5 Western Blot Analysis: Kidney, Liver and Tumor Samples 
To determine the expression and localization of key apoptotic factors, western 
blot analysis was performed on flash frozen tissue samples from the in-vivo studies. 
Tissue samples included liver, kidneys and tumor, of each mouse. The tissues were 
homogenized and fractionated into nuclear, cytoplasmic and mitochondrial fractions (as 
described in materials and methods). Western blot analysis was carried out with 50ug of 
protein from cytosolic and mitochondrial fractions and the use of Bax, Bad, Cytochrome 
c and actin antibodies allowed for qualitative comparisons of the levels of these proteins 
in each tissue and fraction. 
Liver samples were prepared into cytosolic and mitochondrial fractions and 
probed for key apoptotic factors as mentioned previously. As shown in figure 3-19a no 
changes in the levels of apoptotic factors (Bax, Bad and Cytochrome c) were observed in 
the cytoplasmic fraction. Furthermore, figure 3-19b demonstrates that the mitochondrial 
fractions did not exhibit any changes in the levels of Bax and Cytochrome c. 
Kidney samples were then analyzed by western blot analysis, from figure 3-20a 
shows that the cytosolic component did not have any drastic changes in the levels of Bax, 
Bad, and Cytochrome c. As observed in figure 3-20b the kidney mitochondrial fraction 
did not show significant changes in the level of Bax and Cytochrome c. 
Tumor samples analyzed by western blot demonstrated interesting preliminary 
results. In particular, figure 3-2la shows that the cytosolic fraction of tumor cells has an 
increase in the level of Cytochrome c in the Tamoxifen and the PST + Tamoxifen treated 
tissues. The pro-apoptotic Bad protein had increased levels in the cytosol of PST treated 
tumors more so than any other treatment (figure 3-21a). Mitochondrial fractions prepared 
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from tumor samples exhibit a distinct increase in the level of Bax protein in the PST + 
Tamoxifen treated tumor (figure 3-21b). 
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Figure 3-19a: Mouse Liver Cytosolic Fraction 
Placebo PST TAM PST + TAM 
Figure 3-19a: Mouse liver cytosolic fraction. Liver tissue was homogenized and cytosolic fractions were 
isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel and 
immunoblotted for Bad, Bax, Cyt c and Actin. 
Figure 3-19b: Mouse Liver Mitochondrial Fraction 
Placebo PST TAM PST + TAM 
Figure 3-19b: Mouse liver mitochondrial fraction. Liver tissue was homogenized and mitochondrial 
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel 
and immunoblotted for Bax and Cyt c. 
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Figure 3-20a: Mouse Kidney Cytosolic Fraction 
Placebo PST TAM PST+TAM 
Anti Actin-> 
Anti Cyt C -» 
Anti Bax-» 
Anti Bad-> 
Figure 3-20a: Mouse kidney cytosolic fraction. Kidney tissue was homogenized and cytosolic fractions 
were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel and 
immunoblotted for Bad, Bax, Cyt c and Actin. 
Figure 3-20b: Mouse Kidney Mitochondrial Fraction 
Placebo PST TAM PST + TAM 
Anti Cyt C-> 
Anti Bax -> 
Figure 3-20b: Mouse kidney mitochondrial fraction. Kidney tissue was homogenized and mitochondrial 
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel 
and immunoblotted for Bax and Cyt c. 
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Figure 3-21a: Mouse Tumor Cytosolic fraction 
Placebo PST TAM PST + TAM 
Figure 3-21a: Mouse tumor cytosolic fraction. Tumor tissue was homogenized and cytosolic fractions 
were isolated as per protocol. Approximately 50ng of protein were loaded on polyachrylamide gel and 
immunoblotted for Bad, Bax, Cyt c and Actin. 
Figure 3-21b: Mouse Tumor Mitochondrial Fraction 
Placebo PST TAM PST + TAM 
Figure 3-21b: Mouse tumor mitochondrial fraction. Tumor tissue was homogenized and mitochondrial 
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel 
and immunoblotted for Bax and Cyt c. 
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CHAPTER 4: DISCUSSION 
The holy grail of anti-cancer therapy is selective elimination of cancer cells 
without affecting normal tissues. In the present work we demonstrate that PST is very 
selective and efficient in inducing apoptotic cell death in two different breast cancer cell 
lines without affecting the non-cancerous cells. In addition, we observed that treatment 
with low doses of Tamoxifen and PST had a synergistic effect in inducing apoptosis in 
cancerous MCF-7 and Hs578-T cells. Furthermore our results suggest that both these 
compounds may be inducing apoptosis by synergistically destabilizing mitochondria in 
cancer cells selectively. 
4.1 Synergy between PST and Tamoxifen is Estrogen Receptor Pathway 
Independent 
Tamoxifen, is a well established antagonist to estrogen receptor that primarily 
induces apoptosis in ER positive breast cancer cells by modulation of gene expression. 
Interestingly, recent research has indicated that besides ER-mediated genomic effects, 
Tamoxifen induces mitochondrial destabilization and apoptosis in an ER- independent 
manner in several ER negative cancer cell lines (Mandlekar, Kong 2001). 
We used Tamoxifen in combination with PST to see if there is a synergistic 
effect. Indeed, our results using Hoechst staining clearly indicated that lower 
concentrations of 0.5uM PST and 5uM Tamoxifen together induced apoptosis in higher 
numbers than either compound alone in breast cancer MCF-7 cells. At a period of 72 
hours the apoptotic index of 0.5uJVI PST increased by approximately 20% when 
incubated along with 5uM Tamoxifen. We validated this result by quantifying the 
synergistic effect using flow cytometry and observed that annexin V binding gave similar 
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synergistic profiles in the MCF-7 cells, were in which the apoptosis inducing potential of 
PST at a low dose of 0.5 uM increased by 20% upon combined 5uM Tamoxifen 
incubation. The TUNEL assay carried by flow cytometry revealed that 0.5 uM PST 
exhibited a approximate 4% increase in apoptotic induction when combined with 5 uM 
Tamoxifen, this is far less than the result obtained in the annexin-V result, however it can 
be explained as DNA knicks are a later stage event in apoptosis, when cells undergo 
membrane blebbing, however phosphatidyl serine flipping (as observed by annexin-V 
binding) is an early stage apoptotic marker were cells are still in-tact. Therefore at 72 
hours it is expected that most cells will exist in the later stage of apoptosis, in which 
condensation of DNA, membrane blebbing and cell shrinking occurs (Duke et. al. 1996). 
This therefore would pose challenges in the gating of these cells in the flow cytometry 
machine. It would be interesting to look at these stains at earlier time points, however due 
to access restrictions we were only able to gain accurate data for the 72 hour time period. 
Our result show that the synergistic effect was also observed in ER negative 
breast cancer cells (Hs578-T). This effect however was observed at higher Tamoxifen 
concentrations. Specifically we found that the apoptotic index of 0.5uM PST was 
increased by 20% when incubated in combination with lOuM Tamoxifen, where as 
lOuM Tamoxifen treatment on its own did not induce any apoptosis in the Hs578-T cell 
line. This result therefore demonstrated that the synergistic effect is ER independent and 
potentially plays a role on mitochondria. 
4.2 Role of Mitochondria in Synergistic Response 
Differences between the mitochondria of cancerous versus normal cells have been 
researched intensely (Don, Hogg 2004, Villa, Doglia 2004). As previously discussed, 
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many cancerous cells have an altered metabolism, mitochondrial DNA mutations and 
altered membrane compositions (Green, Kroemer 2004, Villa, Doglia 2004, Modica-
Napolitano, Singh 2002, Polyak et. al. 1998). 
Increases in the total whole cell ROS have been linked to destabilization of 
mitochondria (Fluery et. al. 2002). We looked at total ROS production in both MCF-7 
(ER+) and Hs578-T (ER-) cells. We found that the combined treatment of 0.5uM PST 
and 5uM Tamoxifen induced greater total ROS then either compound separately in both 
the ER+ MCF-7 (ER+) and Hs578-T (ER-) cells. 
Depolarization of the mitochondrial membrane potential is essential for 
mitochondrial induced apoptosis (Green, Kroemer 2004, Yuan et. al. 2001). We 
confirmed this effect by JC-1 staining to observe the collapse of the mitochondrial 
membrane potential upon PST and Tamoxifen treatment. It was found that the combined 
treatment of PST and Tamoxifen reduced mitochondrial membrane potential in both 
MCF-7 (ER+) and H-578-T (ER-) cells upon 48 hour treatment. 
Previous work has indicated that PST has mitochondrial targets which allow for 
selective induction of apoptosis (McLachlan et. al. 2005). Furthermore current research 
indicates that Tamoxifen has the ability to induce apoptosis through mitochondrial 
dysfunction, independently of its function as an estrogen receptor antagonist (Mandlekar, 
Kong 2001, Moreire et. al. 2006). To verify if mitochondria are being affected by the 
combined treatment of PST and Tamoxifen we performed ROS measurements directly on 
isolated mitochondria. Mitochondria from MCF-7 (ER+) and Hs578-T (ER-) cells were 
isolated and a HRP/Amplex Red ROS assay was carried out. Furthermore, we used 
Paraquat as a positive control. Paraquat induces ROS by disruption of the electron 
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transport chain (Mollace et. al. 2003). We found that the combined treatment of 0.5uM 
PST and 5(J.M Tamoxifen induced mitochondrial ROS increases in greater amount then 
either compound alone and to the same extent in both cell lines investigated. Indicating 
that both compounds (Tamoxifen and PST) target specific regions of the mitochondria 
and inducing increases in ROS production. 
Mitochondrial membrane permeablization plays a key role in apoptosis by 
releasing caspase activators such as Cytochrome c (Fernadez-Chenca 2003, Duchen 
2004, Green, Reed 1998). We observed Cytochrome c leakage from isolated MCF-7 
mitochondria. We found that a minimum of 1 uM PST was required to induce cytochrome 
c leakage from isolated mitochondria. Intersestingly 0.5uM PST was found to be 
insufficient to cause cytochrome C release, however when treated in combination with 
5uM Tamoxifen we began to see mitochondrial Cytochrome c leakage. This result further 
supported the previous observation that the mitochondria seem to be targets of both PST 
and Tamoxifen in inducing destabilization of mitochondrial membrane leading to 
apoptosis. 
4.3 PST and Tamoxifen Treatment Does Not Induce Apoptosis In Normal Cells 
The observations of synergy between PST and Tamoxifen on whole cells as well 
as isolated mitochondria supports the hypothesis that vulnerability of cancer cell 
mitochondria could be used as cancer specific target to induce apoptosis selectively in 
cancer cells. However to verify the selectivity we chose to work with NHF cell model, 
NHF cells were chosen because of the relative ease of use and maintenance, we 
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encountered problems with contamination from company stocks of normal breast 
fibroblast cells (Hs578-Bst). 
Previous work with anticancer compounds has led to the discovery of many 
clinically used chemotherapeutics which target cancerous cells non-selectivly and 
therefore have drastic side-effects (Yeung et. al. 1999, Boos, Stopper 1999). PST has 
been previously observed to exhibit little toxicity to normal cell lines (McLachlan et. al. 
2005). We therefore tested the combined effect of PST and Tamoxifen on normal human 
fibroblasts to evaluate any potential toxic effects. 
From our analysis of Hoechst staining it was found that no clear indication was 
observed of apoptotic induction in NHF cells at all concentrations of PST and Tamoxifen 
studied. Observing the whole cell ROS we found that there was no apparent increase in 
whole cell ROS when compared to control untreated NHF cells. Furthermore it was 
found that upon treatment of isolated mitochondria from NHF cells we did not see any 
significant increase in ROS production from control. Likewise JC-1 staining indicated 
that the mitochondrial membrane potential in these cells remains in tacked even when 
challenged at the high luM PST and lOuM Tamoxifen concentrations. Therefore we 
observed that the synergistic effect is specific towards cancer cells. 
4.4 Localization of Key Apoptotic Factors in PST Induced Apoptosis 
The localization and expression of pro/anti-apoptotic proteins dictate whether a 
cell undergoes apoptosis or survives. Some Bcl-2 proteins localize to different 
compartments within the cell. During survival and cell proliferation, pro-apoptotic 
proteins such as Bax are generally compartmentalized in the cytosol while the anti-
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apoptotic proteins such as Bcl-2 and Bcl-xl are found on the mitochondrial membrane 
and endoplasmic reticulum (Kuwana, Newmeyer 2003). Upon encountering a stress 
signal, the pro-apoptotic protein Bax will migrate to the outer mitochondrial membrane 
and cause the dysfunction of mitochondrial membrane potential (Goping et. al. 1998). 
One of the key stresses imposed on a cell that tips the balance between pro/anti-apoptotic 
state is the level of reactive oxygen species present within the cell. It is thought that ROS 
increases can be tolerated in cancer cells by the up-regulation of proteins such as Bcl-2 
and Bcl-xl, which protect the mitochondria from mitochondrial membrane collapse 
(Harris, Thompson 2000). However if the ROS condition inside a cell is too high then 
apoptotic cell death is mediated by the up-regulation and activation of anti-apoptotic 
proteins such as Bax, this in turn causes Bax to migrate to the mitochondrial membrane 
were it is thought to interact with the protein transition pore complex (MPTP) and cause 
mitochondrial apoptotic factors such as Cytochrome c to be released (Harris, Thompson 
2000). 
Here we found Bax localization to the mitochondria following PST treatment and 
direct evidence for Cytochrome c leakage. In both MCF-7 and Hs578-T cells we found 
localization of Bax protein to the mitochondria, as well as Cytochrome c leakage after 48 
hours of luM PST treatment. This may be attributed to increases in reactive oxygen 
species caused by direct PST interaction with mitochondria. Interestingly, we found that 
levels of Bad protein were increased in the treated cytosolic fraction of both cell lines. 
This result is particularly interesting because it suggests that there is up-regulation of Bad 
protein expression in both cell lines since Bad does not have a mitochondrial binding 
domain and predominantly resides in the cytosol. Bad protein acts by sequestering and in-
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activating Bcl-2 protein (Kuwana, Newmeyer 2003). When looking at the relative levels 
of pro/anti-apoptotic proteins in the normal NHF cell line we did not see any significant 
differences in any of the protein levels. Due to the previous result that PST can directly 
cause release of Cytochrome c at concentrations of 1 uM we therefore reason that PST 
both increases levels of ROS leading to apoptotic susceptibility as well as directly 
permeabilizing the mitochondrial membrane. 
In future studies it should be noted that both Actin and Succinate Dehydrogenase 
controls should be run in both treated and control samples to give a reflection of relative 
purity in the sample. 
Caspases are apoptotic messengers; their role is to propagate the apoptotic signal 
towards a state of cell suicide. Caspase-8 activation indicates extrinsic apoptotic signaling 
when occurring at early time points (Plesnila et. al. 2001). Using a cell membrane 
permeable caspase-8 substrate we found that late activation of caspase-8 occurs in both 
Hs578-T (48 hour) and MCF-7 (24 hour) cells indicating that caspase-8 activation occurs 
in a later stage of apoptosis induction. The difference in time of activation of caspase-8, 
we reason, is due to the fact that MCF-7 cells are caspase-3 deficient (Essmann et. al. 
2004), and therefore a greater reliance on caspase-8 and other apoptogenic factors is 
required to bi-pass caspase-3 induced apoptosis in MCF-7 cells. 
4.5 MCF-7 Cells Do Not Become Resistant to PST Treatment 
Resistance to treatment is a major obstacle in chemotherapeutic development and 
research. Cancer cells have the capacity to up-regulate ATP-binding cassette transporter 
(ABC transporters) genes which give it the ability to reduce the amount of xenobiotics 
(drugs, toxins), as well as endobiotics within the cell and therefore reduce the effect of a 
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specific drug (Trock et. al. 1997). Therefore, to observe any resistance of MCF-7 cells to 
PST treatment we exposed these cells to prolonged sub-lethal dose of 25nM or 50nM 
PST for a period of 20 days, we did not observe any changes in the sensitivity of MCF-7 
cells to the lethal dose of luM PST treatment. This result indicates that PST does not 
induce mechanisms of resistance in MCF-7 cells. 
4.6 In-vivo Study of PST and Tamoxifen Synergy 
Previous athymic nude mouse models that were used to establish colon tumors 
would not allow for MCF-7 tumorigenisis. We used a mouse model for breast cancer 
consisting recombinase deficient RAG 2M mice as described by Webb et. al. 2007. Each 
mouse had to be injected with a slow release 60-day 17-|3 estradiol tablet 24 hours prior 
to cancer cell injection. Approximately 6 X 106 human breast cancer (MCF-7) cells were 
injected in the right hind flank. We were successful in establishing tumors in all the mice 
in our study and injected them with PST or Tamoxifen accordingly. At this point all data 
is preliminary since the experimental procedure had to be standardized for these mice. 
Specific problems were encountered over the course of the experiment. For 
instance these mice contained fur making it difficult to measure tumor size progression 
using calipers. Also, over the course of the experiment two of the mice died in their cage 
(one PST and one Tamoxifen), therefore reducing the number of mice in the experiment. 
Tamoxifen was prepared in peanut oil as described previously (Paine-Murrieta et. al. 
1997) because it is lipid soluble. However, this method of administering Tamoxifen gave 
rise to complications with respect to absorption. When dissecting the mice, oil pockets 
were found in the subcutaneous portions indicating that the oil had not properly absorbed 
into the body. Furthermore, growth rates of the tumors varied: some mice exhibited 
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tumors before others; the mice were treated accordingly to when tumor sizes reached 
approximately 5mm in diameter. Therefore, these preliminary results must be repeated 
with a larger sample of mice in order to make the findings statistically significant. 
Despite complications, certain changes to the protocol are proposed here to 
enhance the reproducibility of the experiment. Nude mice were not used for modeling 
breast cancer because it is notoriously difficult to establish hormone dependent tumors 
through subcutaneous injections (Giovanella, Fogh 1985). RAG 2M mice were used 
because injected MCF-7 cells were reported to establish into tumors (Webb et. al. 2007). 
However, It has been reported that the use of matrigel greatly increases the 
tumorigenecity of MCF-7 cells in nude athymic mice (Fridman et. al. 1991). Therefore an 
alternate approach would be to use matrigel to establish MCF-7 tumors, which are 
relatively same size prior to insertion into immunocompromised mice. This model would 
have the advantage of increasing the ability to monitor tumor progression over the course 
of treatment, since the tumors would be relatively the same size and clearly visible. 
Work by Yue et. el 1994. showed that once injected into the subcutaneous cavity, 
MCF-7 cells transfected with human placental aromatase gene (MCF-7a) provide a non-
ovarian source of estrogen in nude BALB/c athymic mice. Furthermore, this work 
showed that these transfected cells (MCF-7a) developed into tumors rapidly and 
consistently when mice were given androstenedion (aromatase substrate) at a 
concentration of O.lmg/per mouse/per day (injected subcutaneously) when compared 
with mice transfected with a control vector (MCF-7c). Therefore these considerations 
could be taken into account when developing future mouse models in our in-vivo study to 
establish more accurate and reliable data. 
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CHAPTER 5: FUTURE PERSPECTIVES 
Critical hurdles exist in the research of PST as an anticancer compound. One of 
the major obstacles is the development of a synthetic compound produced by an organic 
process. Our collaborator Dr. McNaulty, an organic chemist at McMaster University is 
currently working on ways to simplify the organic synthesis of PST and has successfully 
developed structural analogues of PST, which help to deduce the minimum 
pharmacophore required for activity (McNulty et. al 2005). It is possible that an active 
derivative of PST may retain synergistic properties, and when combined ^with Tamoxifen 
may be used to treat a variety of cancer types. 
The development of a synthetic PST derivative will allow for tritium or carbon-14 
labeling. Radioactive labeling will allow us to therefore pinpoint the exact biochemical 
target of PST, and therefore expand our knowledge in cancer cell susceptibility. 
The ability of Tamoxifen to destabilize the mitochondria enables testing of 
combinatorial treatment (PST and Tamoxifen) in a variety of cell lines, not just breast 
carcinoma. Currently, exactly that is being applied to a human melanoma cell line, and in 
the future, we will investigate the synergistic response in a host of different cancer cells 
(ex. Lymphoma, Colon, Pancreatic, Prostate, Lung...etc.) in order to observe any 
relevant increases in the apoptotic index of combined treatment versus single treatment 
alone. 
Changes in protein expression and localization caused by PST treatment can be 
further investigated by 2-dimensional in gel electrophoresis (2-DIGE). Control and 
treated cellular fractions (cytosolic and mitochondrial) can be fluorescently labeled with 
separate dyes which incorporate into either lyseine or cysteine residues and give two 
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distinct colors green or red. The fractions can then be run together on the same 2-
dimensional gel and the relative intensity of each spot, with respect to their color, can 
determine the relative amount of up-regulation or down-regulation of the proteins in 
specified cellular fractions (mitochondrial and cytosolic). 
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CHAPTER 6: Conclusions 
We have clearly demonstrated the apoptosis-inducing activity of PST in breast 
cancer cells, with no detectable toxicity to non-cancerous cells. The intrinsic pathway of 
apoptosis was observed by mitochondrial destabilization through ROS increases and 
Cytochrome c release in both Hs578-T and MCF-7 breast cancer cell lines, without any 
indication of this occurrence in the normal counterpart NHF cell line. Interestingly, there 
was a synergistic apoptotic effect with combined treatment of PST and Tamoxifen in 
both estrogen receptor positive (MCF-7) and estrogen receptor negative (HS578-T) cell 
lines. More importantly it was established that both of these drugs target cancer cell 
mitochondria selectively indicating that the observed effect is independent of estrogen 
receptor. Furthermore, we developed for the first time in our lab, a human breast cancer 
(MCF-7) mouse model using RAG 2M mice, although the results are inconclusive, they 
do open the window for future experiments on the synergistic response of PST and 
Tamoxifen in-vivo. Therefore a new window of opportunity has now been opened to 
develop novel combination therapy for cancer treatment. 
105 
REFERENCES 
1. Albanell J, Baselga J. Unravelling resistance to trastuzumab (herceptin): insulin-like 
growth factor-1 receptor, a new suspect. Journal of the National Cancer Institute. 2001; 
93: 1830-1832. 
2. Ames B N, Gold L S, Willett W C. The causes and prevention of cancer. 
Proceedings of the National Academy of Sciences. 1995; 92 (12): 5258-65. 
3. Amundadottir L.T., Merlino G., Dickson R.B. Transgenic mouse models of breast 
cancer. Breast Cancer Res Treat. 1996; 39:119-135. 
4. Ashkenazi A, Dixit V M. Death receptors; signaling and modulation. Science. 1998; 
281: 1305-1308. 
5. Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast 
cancer: Where are we now? European Journal of Cancer. 2005; 41: 1667-1677. 
6. Benedict M A, Hu Y, Inohara N, Nunez G. Expression and functional analysis of 
Apaf-1 isoforms: Extra Wd-40 repeat is required for cytochrome c binding and regulated 
activation of procaspase-9. Journal of Biological Chemistry. 2000; 275: 8461-8468. 
7. Boose G, Stopper H. Genotoxicity of several clinically used topoisomerase II 
inhibitors. Toxicology Letters. 2000; 116: 7-16. 
8. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, 
Provincial / Territorial Cancer Registries, Public Health Agency of Canada Canadian 
Cancer Statistics 2008. Canadian Cancer Society. 2008. www.cancer.ca 
9. Carafoli E. Mitochondria and disease. Mol Aspects Med. 1980; 3: 295-429. 
10. Cardiff RD. Validity of mouse mammary tumor models for human breast cancer: 
comparative pathology. Microscopy Research and Technique. 2001; 52:224-230. 
106 
11. Casciola-Rosen L, Nicholson D W, Chong T, Rowan K R, Thornberry N A, Miller D 
K, Rosen A. Apopain / CP32 cleaves proteins that are essential for cellular repair: a 
fundamental principle of apoptotic death. Journal of Experimental Medicine. 1996; 183: 
1957-64. 
12. Chabner B A, Roberts T G Jr. Timeline: Chemotherapy and the war on cancer. 
Nature Reviews Cancer. 2005; 5(1): 65-72. 
13. Chernyak B V, Bernardi P. The mitochondrial permeability transition pore is 
modulated by oxidative agents through both pyridine nucleotides and glutathione at two 
separate sites. European Journal of Biochemistry. 1996; 238: 623-630. 
14. Chinnadurai G, Lutz R J. A conserved domain in Bak, distinct from BH1 and BH2 
mediates cell death and protein binding functions. The EMBO Journal. 1995; 14 (22): 
5589-5596 
15. Chou JJ , Li H, Salvesen G S, Yuan J, Wagner G. Solution structure of BID, an 
intracellular amplifier of apoptotic signaling. Cell. 1999; 96(5): 615-24. 
16. Cunha KS., Reguly ML., Graf U., de Andrade HHR., Taxanes: the genetic toxicity of 
paclitaxel and docetaxel in somatic cells of drosophila melangaster. Mutagenesis. 2001; 
16:79-84. 
17. Debatin K M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunology 
Immunotherapy. 2004; 53(3): 153-9. 
18. Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene. 2003; 22: 8543-
8567. 
19. Don A, Hogg P. Mitochondria as cancer drug targets. Trends in Molecular Medicine. 
2004; 10(8): 372-377. 
107 
20. Dragowska W.H., Verreault M., Yapp D.T., Warburton C , Edwards L., Ramsey E.C., 
Huxham L.A., Minchinton A.I., Gelmon K., Bally M.B. Decreased levels of hypoxic 
cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are 
associated with hyperactivation of the mTOR pathway: therapeutic implications for 
combined thereapy with rapamycin. Breast Cancer Res Treat. 2007; 106:319-331. 
21. DuchenM R. Roles of mitochondria in health and disease. Diabetes. 2004; 53: 96-
102. 
22. Duffy MJ. Predictive markers in breast and other cancers: a review. Clinical 
Chemistry. 2005; 51: 494-503. 
23. Duke RC, Ojcius DM, Young JD. Cell suicide in health and disease. Scientific 
America. 1996: 80-7. 
24. Dunning AM., Healey CS., Pharoah PD., Teare MD., Ponder B., Easton DF. A 
systemic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiology. 
1999; 8:843-854. 
25. Earnshaw C W, Martins M L, Kaufman H S. Mammalian caspases; structure, 
activation, substrates and functions during apoptosis. Annual Reviews in Biochemistry. 
1999; 68:383-424. 
26. Essmann F., Engels IH., Totzke G., Schulze-Osthoff K., Janicke RU. Apoptosis 
resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of P53 
and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibited event. 
Cancer Research. 2004; 64:7065-7072. 
27. Fantin V R, Leder P. F16, a mitochondriotoxic compound, trigger apoptosis or 
necrosis depending on the genetic background of the target carcinoma cell. Cancer 
108 
Research. 2004; 64: 329-36. 
28. Fernadez-Chenca C. Redox regulation and signaling lipids in mitochondrial 
apoptosis. Biochemical and Biophysical Research Communications. 2003; 304: 471-479. 
29. Fluery C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell 
death signaling. Biochimie. 2002; 84: 131-41. 
30. Fridman, R., Kibbey, M. C, Royce, L S., Zain, M., Sweeney, T. M., Jicha, D. 
L,Yannelli, J. R., Martin, G. R., and Kleinman, H. K. Enhanced tumor growth of both 
primary and established human and murine tumor cells in athymic mice after coinjection 
with matrigel. Journal of National Cancer Institute. 1991; 83:169-11 A. 
31. Fulda S., Scaffidi C , Susin S.A., Krammer P.H., Kroemer G., Peter M.E., Debatin 
K.M. Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factoris by 
betulinic acid. The Journal of Biological Chemistry. 1998; 273 (51): 33942-33948. 
32. Gayther S., Warren W., Mazoyer S., Russel P., Harrington P., Chiano M., Seal S., 
Hamoudi R., van Rensburg E., Dunning A., Love R., Evans G., Easton D., Clayton D., 
Stratton M., Ponder B. Germline mutations of the BRCA1 gene in breast and ovarian 
cancer families provide evidence for a genotype-phenotype correlation. Nature. 1995; 11: 
428-433. 
33. Gelmann EP. Tamoxifen for the treatment of malignancies other then breast and 
endometrial carcinoma. Semin Oncol. 1997; 24: S65-S75. 
34. Giovanella, B. C, and Fogh, J. The nude mice in cancer research. Advancements in 
Cancer Research. 1985; 44: 69-120. 
109 
35. Goping I S, Gross A, Lavoie J N, Nguyen M, Jemmerson R, Roth K, Korsmeyer S J, 
Shore GC. Regulated targeting of BAX to mitochondria. Journal of Cell Biology. 1998; 
143(1): 207-15. 
36. Green D, Kroemer G. The Pathology of Mitochondrial Cell Death. Science. 2004; 
305: 626-629. 
37. Green D R, Reed J C. Mitochondria and apoptosis. Science. 1998; 281: 1309-1312. 
38. Gross A, Mc Donald J M, Korsmeyer S J. Bcl-2 family members and the 
mitochondria in apoptosis. Genes & Development. 1999; 13: 1899-1911. 
39. Hait WN., Yang JM. The individualization of cancer therapy: the unexpected role of 
P53. Transactions of the American Clinical and Climatological Association. 2006; 117: 
85-101. 
40. Haldar S., Negrini M., Monne M., Sabbioni S., Croce CM. Down-regulation of Bcl-2 
by P53 in breast cancer cells. Cancer Research. 1994; 54: 2095-2097. 
41. Harris M H, Thompson C B. The role of Bcl-2 family in the regulation of outer 
mitochondrial membrane permeability. Cell Death and Differentiation. 2000; 7: 1182-91. 
42. Haslett C. Resolution of acute inflammation and role of apoptosis in the tissue fate of 
granulocytes. Clinical Science. 1992; 83:639-648. 
43. Heerdt AS, Borgan PI. Current status of Tamoxifen use: An update for the 
surgicaloncologist. Journal of Surgical Oncology. 1999; 72: 42-49. 
44. Hirsch T., Susin S.A., Marzo I., Marchetti P., Zamzami N., Kroemer G. Mitochonrial 
permeability transition in apoptosis and necrosis. Cell Biology and Toxicology. 1998; 14: 
141-145. 
110 
45. Hickey J., Raje R., Reid E., Gross M., Ray D., Diclofenac induced in vivo 
nephrotoxicity may involve oxidative stress-mediated massive genomic DNA 
fragmentation and apoptotic cell death. Free Radical Biology & Medicine. 2001; 31: 139-
152. 
46. Hongtae K., Junjie C. New Players in the BRCA1 -mediated DNA Damage 
Responsive Pathway. Molecules and Cells. 2008; 25: 457-461. 
47. Hunter J J, Bond B L, Parslow T G. Functional dissection of the human Bcl-2 protein: 
sequence requirements for inhibition of apoptosis. Molecular Cell Biolology. 1996; 16(3): 
877-883. 
48. Jeremic B. Radiation therapy. Hematology / Oncology Clinics of North America. 
2004;18: 1-12. 
49. Josephine S. M., Singh K.K. Mitochondrial dysfunction in cancer. Mitochondrion 
2004; 755-762. 
50. Josephine S, Modica N, Sing K. Mitochondria as targets for detection and treatment 
of cancer. Expert Reviews. 2002; 1-19. 
51. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of mitochondria in 
tamoxifen-induced cancer cells. Apoptosis. 2005; 10: 1395-1410. 
52. Kerr J F, Wyllie A H, Currie A R. Apoptosis: A basic biological phenomenon with 
wide ranging implications in tissue kinetics. British Journal of Cancer. 1972; 26: 239-
257. 
53. Kim R. Recent Advances in Understanding the Cell Death Pathways Activated by 
Anticancer Therapy. Cancer. 2005; 103(8): 1551-1560. 
54. Kleinsmith, L J. Principles of Cancer Biology. Pearson Benjamin Cummings: 2006 
111 
55. Kohler T., Schill C, Deininger MW., Krahl R., Borchert S., Hasenclever D., Leiblein 
S., Wagner O., Niederwieser D. High Bad and Bax mRNA expression correlate with 
negative outcome in acute myeloid leukemia (AML). Nature. 2002; 16: 22-29. 
56. Korsmeyer S J, Wei M C, Saito M. Proapoptotic cascade activates BID which 
oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell 
death and Differentiation. 2000; 7: 1166-1173. 
57. Kroemer G, Reed J C. Mitochondrial control of cell death. Natural Medicine. 2000; 
6:513-519. 
58. Kroemer, G. Mitochondrial control of apoptosis: an introduction. Biochemistry and 
Biophysics Research Communications. 2003; 302: 433-435. 
59. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in 
cell death. Physiol Rev. 2007; 87: 99-163. 
60. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green 
DR, Newmeyer DD: Bid, Bax and lipids cooperate to form supramolecular openings in 
the outer mitochondrial membrane. Cell. 2002; 111: 331-342. 
61. Kuwana T., Newmeyer D. Bcl-2 family proteins and the role of the mitochondria in 
apoptosis. Current Opinion in Cell Biology. 2003; 15: 691-699. 
62. Lamarca HL., Rosen JM. Hormones and mammary cell fate: what will I become 
when I grow up? Endocrinology. 2008; 1-6. 
63. Leist M, Nicotera P. The shape of cell death. Biochemistry and Biophysics Research 
Communications. 1997; 236: 1-9. 
64. Levine B., Sinha S., Kroemer G. Bcl-2 family members. Autophagy. 2008; 4 : 600-
606. 
112 
65. Li N, Ragheb K, Lawler G, et al. Mitochondrial complex-I inhibitor rotenone induces 
apoptosis through enhancing mitochondrial reactive oxygen species production. The 
Journal of Biological Chemistry. 2003: 278; 8516-8525. 
66. Li P., Nijhawan D., Budihardjo I., Srinivasula M., Ahmed M., Alnemri S., Wang X. 
Cytochrome c and dATP - dependent formation of Apaf-1 / caspase-9 complex initiates 
an apoptotic protease cascade. Cell. 1997; 91: 479-489. 
67. Lin EY., Jones JG., Li P., Zhu L., Whitney K., Muller W., Pollard JW. Progression to 
malignancy in the polyma middle T oncoprotein mouse breast cancer model provides a 
reliable model for human disease. American Journal of Pathology. 2003; 163(5): 2113-
2126. 
68. Luduena R F, Roach M C, Prasad V, Pettit G R. Biochemical Pharmacology. 1992; 
43: 539. 
69. Mandlekar S, Kong ANT. Mechanisms of Ttamoxifen-induced apoptosis. Apoptosis. 
2001;6:469-77. 
70. Martin NMB. DNA Repair Inhibition and Cancer Therapy. Journal of 
Photochemistry & Photobiology. 2001; 63: 162-70. 
71. McCarthy S, Somayajulu M, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. 
Paraquat Induces Oxidative Stress and Neuronal Cell Death; Neuro-protection by Water-
Soluble Coenzyme Qjo. Toxcology & Applied Pharmacology. 2004; 201: 21-31. 
72. McDonnell J M, Fushman D, Milliman C L, Korsmeyer S J, Cowburn D. Solution 
structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and 
antagonists. Cell. 1999; 96: 625-634. 
113 
73. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human 
breast cancer: an overview. In: McGuire WL,Carbone PP, Vollner EP, eds. Estrogen 
receptors in human breastcancer. New York: Raven Press. 1975; 1-8. 
74. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer 
compound that targets mitochondria specifically in cancer cells to induce apoptosis. 
Apoptosis. 2005; 10(3): 619-30. 
75. McLachlan-Burgess A, McCarthy S, Griffin C, Richer J, Pandey S. The differential 
response induced by exposure to low-dose ionizing radiation in SHSY-5Y and normal 
human fibroblast cells. Applied Biochemistry & Biotechnology. 2006; In Press. 
76. McNulty J, Larichev V, Pandey S. A synthesis of 3-deoxyihydrolycoricine: 
refinement of a structurally minimum Pancratistatin pharmacophore. Bioorganic & 
Medicinal Chemistry Letters. 2005; 1: 15(23): 5315-5318. 
77. Mendlekar S., Kong T. Mechanisms of Tamoxifen-induced apoptosis. Apoptosis. 
2001;6:469-477. 
78. Mense S., Hei T., Ganju R., Bhat H. Phytoestrogense and breast cancer prevention: 
possible mechanism of action. Environmental Health Perspectives. 2008; 116: 426-433. 
79. Modica-Napolitano J S, Singh K. Mitochondria as targets for detection and treatment 
ofcancer. Expert Reviews in Molecular Medicine. 2002; 11: 1-19. 
80. Modica-Napolitano J S, Singh K. Mitochondrial dysfunction in cancer. 
Mitochondrion. 2004; 755-762. 
81. Moll, U. M., Riori, G., and Lavine, A. J. Two distinct mechanisms alterp53 in breast 
cancer mutation and nuclear exclusion. Proclaimed National Academic Science. 1992; 
89: 7262-7266. 
114 
82. Mollace V., Iannone M., Muscoli C , Palma E., Granato T., Rispoli V., Nistico R., 
Rotiroti D., Salvemini D. The role of oxidative stress in paraquat-induced neurotoxicity 
in rats: protection by non peptidyl superoxide dismutase mimetic. Neuroscience Letters. 
2002;335:163-166. 
83. Moreira P, Custodio J, Morena A, Oliveira C, Santos M. Tamoxifen and Estradiol 
interact with the flavin mononucleotide site of mitochondrial complex 1 leading to 
mitochondrial failure. Journal of Biological Chemistry 2006; 281: 10143-52. 
84. Naderi J, Hung M, Pandey S. Oxidative stress-induced apoptosis in dividing 
fibroblasts involves activation of p38 MAP kinase and over-expression of Bax: 
Resistance of quiescent cells to oxidative stress. Apoptosis. 2003; 8: 91-100. 
85. Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, Ghafourifar 
P. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating 
mitochondrial nitric oxide synthase. Cancer Res. 2007; 67: 1282-90. 
86. Neuzil J., Tomasetti M., Zhao Y., Dong L., Birringer M., Wang X., Low P., Wu K., 
Salvatore B., Ralph S. Vitamine E analogues, a novel group of "mitocans", as anticancer 
agents: the importance of being redox-silent. Molecular Pharmacology. 2007; 71: 1185-
1199. 
87. Nieves-Neira W., Pommier Y. Apoptotic response to campthecin and 7-
hydroxystaurosporine (ucn-1) in the 8 human breast cancer cell lines of the NCI 
anticancer drug screen: multifactorial relationships with topoisomerase I, protein kinase 
C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer. 1999; 82:396-404. 
88. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicology Letters. 
2004; 149:19-23. 
115 
89. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast 
cancer: potential diagnostic and therapeutic applications. Oncologist. 2004; 9(4): 361-77. 
90. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, Lenaers G. Loss 
of OP A1 perturbates the mitochondrial inner membrane structure and integrity, leading to 
cytochrome c release and apoptosis. Journal of Biological Chemistry. 2O03; 278: 7743-
7746. 
91. Paine-Murrieta G.D., Taylor C.W., Curtis R.A., Lopez M.H., Dorr R.T., Johnson 
C.S., Funk C.Y., Thompson F., Hersh E.M. Human tumor models in the severe combined 
immuno deficient (scid) mouse. Cancer Chemother Pharmacol. 1997; 40: 209-214. 
92. Pandey S, Smith B, Walker P R, and Sikorska M. Caspase-dependent and 
independent cell death in rat hepatoma 5123tc cells. Apoptosis. 2000; 5: 265-275. 
93. Pandey S., Kekre N., Naderi J. Induction of apoptotic cell death specifically in rat and 
human cancer cells by pancratistatin. Artificial Cells, Blood Substitutes, and 
Biotechnology. 2001;33:1-17. 
94. Parlo RA, Coleman PS. Enhanced rate of citrate export from cholesterol-rich 
hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of 
mitochondrial membrane cholesterol. Journal of Biological Chemistry. 1984; 259: 9997-
10003. 
95. Pedram A., Razandi M., Wallace D., Levin E. Functional estrogen receptors in the 
miotchondria of breast cancer cells. Molecular Biology of the Cell. 2006; 17: 2125-2137. 
96. Pettit R., Backhaus A., Boyd R., Meerow W. Antineoplastic Agents 256: Cell Growth 
Inhibitory Isocarbostyrils from Hymenocallis. Journal of Natural Products. 1993; 
56:1682. 
116 
97. Plesnila N., Zinkel S., Le DA., Armin-Hanjani S., Wu Y., Qlu J., Chlarugi A., 
Thomas SS., Kohane DS., Korsmeyer SJ., Moskowitz MA. Bid mediates neuronal cell 
death after oxygen glucose deprivation and focal cerebral ischemia. PNAS. 2001; 98(26): 
15318-15323. 
98. Polyak K, Li Y, Zhu H, Lengauer C, Willson J K, Markowitz S D, Trush M A, 
Kinzler K W, Vogelstein B. Somatic mutations of the mitochondrial genome in human 
colorectal tumors. Nature Genetics. 1998; 20: 291-3. 
99. Reed J C. Mechanisms of Bcl-2 family protein function and dysfunction in health and 
disease. Behring Institute Mitteilungen. 1996; 97: 72-100. 
100. Reed J C. Warner-Lambert/Parke-Davis Award Lecture: Mechanisms of Apoptosis. 
American Journal of Pathology. 2000; 157(5): 1415-1426. 
101. Reed J C. Apoptosis-based therapies. Nature Reviews in Drug Discovery. 2002; 1: 
111-121. 
102. Reedy S., Wang X., Samaha H., Lubet R., Steele E., Kelloff J., Rao V. Cancer 
Research. 1997; 57: 420-425. 
103. Sattler M, Liang H, Nettesheim D, Meadows R P, Harlan J E, Eberstadt M, Yoon H 
S, Shuker S B, Chang B S, Minn A J, Thompson C B, Fesik S W. Structure of Bcl-xL-
Bak Peptide Complex: Recognition Between Regulators of Apoptosis. Science. 1997; 
275(5302): 983 - 986. 
104. Selvanayagam, P., Rajaraman, S. Detection of mitochondrial genome depletion by a 
novel cDNA in renal cell carcinoma. Lab. Invest. 1996; 74: 592-599. 
105. Shao W., Brown M. Advances in estrogen receptor biology: prospects for 
improvements in targeted breast cancer therapy. Breast Cancer Res. 2004; 6: 39-52. 
117 
106. Shimizu S, Narita M, Tsujimoto Y: Bcl-2 family proteins regulate the release of 
apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999; 399: 483-
487. 
107. Smith CL., O'Malley BW. Coregulator Function: A Key to Understanding Tissue 
Specificity of Selective Receptor Modulators. Endocrine Reviews. 2004; 25(1): 45-71. 
108. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowsi H, Pandey S. 
Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection 
by Coenzyme Qio. Neurobiology of Disease. 2005; 18: 618-627. 
109. Soto-Cerrato V., Llagostera E., Montaner B., Scheffer G.L., Perez-Tomas R. 
Mitochondria-mediated apoptosis operating irrespective of multidrug resistence in breast 
cancer cells by the anticancer agent prodigiosin. Biochemical Pharmacology. 2004; 1345-
1352. 
110. Susin S A, Lorenzo H K, Zamzami N, Marzo I, Snow B E, Brothers G M, Mangion J, 
Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett D R, Aebersold R, Siderovski 
D P, Penninger J M, Kroemer G. Molecular characterization of mitochondrial 
apoptosis-inducing factor. Nature. 1999; 397(6718): 441-6. 
111. Szabo C. Mechanisms of cell necrosis. Critical Care Med. 2005; 33: 530-534. 
112. Trock BJ., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-
analysis of MDRl/gpl70 expression and its possible functionnal significance. Journal of 
the National Cancer Institute. 1997; 89(13): 917-931. 
113. Verhagen AM., Ekert PG., Pakusch M., Silke J., Connolly LM., Reid GE., Moritz 
RL., Simpson RJ., Vaux DL. Identification of DIABLO, a mammalian protein that 
promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000; 102:43-53. 
118 
114. Villa, A M, Doglia S M. Mitochondria in tumor cells studied by laser scanning 
confocal microcopy. Journal of Biomedical Optics. 2004; 9: 385-94. 
115. Wang J., Barnes RO., West NR., Olson M., Chu JE., Watson PE. Jabl is a target of 
EGFR signaling in ERa negative breast cancer. Breast Cancer Research. 2008; ahead of 
print. 
116. Webb MS., Johnstone S., Morris TJ., Kennedy A., Gallagher R., Harasym N., 
Harasym T., Shew CR., Tardi P., Dragowski W., Mayor LD., Baley MB. In-vitro and in-
vivo characterization of a combination chemotherapy formulation consisting of 
vinorelbine and phosphatidylserine. European Journal of Pharmaceutics and 
Biopharmaceutics. 2007; 65: 289-299. 
117. Weinberg R A. How cancer arises. Scientific America. 1996; 40-48. 
118. Willett W., The search for the causes of breast and colon cancer. Nature. 1989; 338: 
389-394. 
119. Wolter K., Hsu Y., Smith C, Nechushtan A., Xi X. G., Youle R. Movement of Bax 
from the cytosol to the mitochondria during apoptosis. Journal of Cell Biology. 1997; 
139: 1281-1292. 
120. Yang E., Zha J., Jockel J., Boise LH., Thompson CB., Korsmeyer SJ. Bad, a 
heterodimeric partner for Bcl-xl and Bcl-2 displaces Bax and promotes cell death. Cell. 
1995;80:285-291. 
121. Yeung T K, Germond C, Chen X, Wang Z The mode of action of taxol: apoptosis at 
low concentration and necrosis at high concentration. Biochemistry and Biophysics 
Research Communications. 1999; 263(2): 398-404. 
119 
122. Yin X., Luo Y., Cao G, Bai G., Pei W., Kuharsky D., Chen J. Bid-mediated 
Mitochondrial Pathway Is Critical to Ischemic Neuronal Apoptosis and Focal Cerebral 
Ischemia. The Journal of Biological Chemistry. 2002; 277(44): 42074-42081 
123. Yuan H., Mutaomba M., Prinz I, Gottlieb R. Differential processing of cytosolic and 
mitochondrial caspases. Mitochondrion. 2001; 1: 61-69. 
124. Yue W., Zhou D., Chen S., Brodie A. A new nude mouse model for postmenopausal 
breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer 
Research. 1994; 54: 5092-5095. 
125. ZhangY., Mclaughlin R., Goodyer C , LeBlanc A. Selective cytotoxicity of 
intracellular amyloid beta peptide 1-42 through p53 and Bax in cultured primary human 
neurons. Journal of Cellular Biology. 2002; 156: 519-529. 
126. Zhai Y.F., Esselman W.J., Oakley C.S., Chang C.C., Welsch C.W. Growth of MCF-7 
human breast carcinoma in sever combined immundeficient mice: growth suppression by 
recombinant interleukin-2 treatment and role of lumphokine-activated killer cells. Cancer 
Immunology Immunotherapy. 1992; 35: 237-245. 
127. Zoratti M, Szabo I. The mitochondrial permeability transition. International Journal 
of Biochemistry, Biophysics and Molecular Biology. 1995; 1241: 139-179.Zou H, 
Henzel W J, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. 
elegans CED -4, participates in cytochrome c- dependent activation of caspase-3. Cell. 
1997; 90: 405-413. 
120 
VITA AUCTORIS 
NAME: Peter Siedlakowski 
PLACE OF BIRTH: Gorzow, Poland 
EDUCATION: University of Windsor 
2006 - 2008 Master's of Science: Biochemistry 
2002 - 2006 Bachelor's of Science: Honour's Biochemistry 
121 
